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Blockade of epidermal growth factor receptor (EGFR) causes tumor regressions in selected patients 
with metastatic colorectal cancer (mCRC); however, residual disease reservoirs typically remain even 
after maximal response to therapy, leading to relapse. Using patient-derived xenografts, we observed 
that mCRC cells surviving EGFR inhibition exhibited gene expression patterns reminiscent of those 
displayed by a quiescent subpopulation of normal intestinal secretory precursors with Paneth-cell 
characteristics. These pseudodifferentiated remnants had reduced expression of EGFR-activating 
ligands, more pronounced activity of human epidermal growth factor 2 (HER2) and human epidermal 
growth factor receptor 3 (HER3), and persistent signaling along the phosphatidylinositol-3-kinase 
(PI3K) pathway compared with untreated tumors. Clinically, residual disease traits were detected in 
lingering tumors of responsive patients and in tumors of individuals who had experienced early 
recurrence. Mechanistically, residual tumor reprogramming was mediated by inactivation of Yes-
associated protein (YAP) – a master regulator of post-injury intestinal epithelium recovery – following 
EGFR neutralization. In preclinical trials, Pan-HER antibodies minimized residual disease, blunted 
PI3K signaling, and induced long-term tumor control after treatment discontinuation. By showing that 
tolerance to EGFR inhibition is typified by the disengagement of an in-built lineage program that drives 
both regenerative signaling during intestinal repair and EGFR-dependent tumorigenesis, our results 
shed light onto CRC lineage plasticity as an adaptive escape mechanism from therapeutic insults and 
suggest opportunities to pre-emptively target residual disease. 
 
 
Single sentence summary: Drug tolerance in EGFR-inhibited mCRC tumors involves Paneth cell-like 







Although many advanced-stage solid cancers regress when treated with therapies that target drivers 
of tumor growth, responses are usually incomplete, owing to the presence of residual cells that 
withstand initial treatment (1). Clinical studies have documented a correlation between depth of 
response to anticancer therapies and progression-free survival (PFS) (2-4), supporting the notion that 
the pool of cancer cells that persist in the face of therapy can ultimately be responsible for therapy-
resistant tumor progression.  
The mechanisms that sustain residual tumor burden remain unclear. Cell line-based experiments 
have shown that exposure to an initial onslaught of potentially lethal growth-inhibitory cues (such as 
anti-cancer agents) prompts the emergence of a drug-tolerant state, in which drug-resistant 
subpopulations arise de novo from a drug-sensitive population (5,6). These ‘drug-tolerant persisters’ 
(5) occasionally divide and fail to undergo cell death under drug pressure; moreover, they resume 
vigorous proliferation when therapy is withdrawn and regain drug sensitivity after a washout period, 
indicating a reversible phenotype that is stochastically attained and relinquished starting from a bulk of 
heterogeneous cells. The pool of drug-tolerant cancer cells that survive initial therapy can evolve 
subclones with more permanent, genetically determined mechanisms of acquired resistance. For 
example, after prolonged drug exposure, EGFR-mutant non-small cell lung cancer (NSCLC) cells that 
tolerate EGFR blockade give rise to newly emerging subpopulations harboring a gatekeeper resistance 
mutation (6,7). 
In vitro studies have crucially contributed to conceptualizing the basic principles of drug tolerance 
to targeted therapies. However, more clinically relevant attempts to understand how these principles 
apply to residual disease in human tumors have been scarce so far (8-10). This is due to inherent 
hurdles when using tumor material from patients, including the difficulty in collecting and analyzing 
residual cells at maximal tumor response, the paucity of clinical specimens from treated patients, and 
a dearth of experimental models that accurately recapitulate fundamental aspects of residual disease 
and recurrence (1). We decided to address this knowledge gap with a focus on metastatic colorectal 
cancer (mCRC), a tumor setting for which the clinical challenge of residual disease is particularly 
germane. Monoclonal antibodies that inhibit EGFR (cetuximab and panitumumab) achieve clinically 
meaningful rates of response in chemorefractory patients with inoperable mCRC tumors (11-15). 
Several laboratories, including ours, have identified a number of genetic alterations that are associated 
with and causally responsible for innate resistance to EGFR blockade in mCRC (16-20). Although 
omitting anti-EGFR therapy in mCRC patients carrying these resistance-associated genotypes has 
refined the identification of sensitive cases, complete regressions remain exceptions. This translates 
into a suboptimal outlook for responsive patients, with only 2-month improvement in progression-free 
survival (PFS) and 6-month improvement in overall survival compared with chemotherapy (15). This 
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evidence highlights the importance of understanding the molecular bases of drug tolerance in EGFR-
inhibited mCRC as a prelude to limiting residual disease and delaying the development of resistance. 
Here we used mCRC patient-derived xenografts (PDXs), captured at maximal response to 
cetuximab, to disentangle the phenotypic and functional ramifications of EGFR inhibition in drug-
tolerant persisters. We report that EGFR blockade in CRC i) disrupts a feed-forward homeostatic circuit 
that maintains tumor reliance on EGFR signals by co-opting pro-regenerative programs active in the 
normal intestine after injury, and ii) unleashes pseudodifferentiation towards an EGFR-independent, 
Paneth cell-like phenotype with alternate therapeutic vulnerabilities. More broadly, this study illustrates 
the importance of lineage-based adaptive reprogramming as a means to evade pathway dependency 








Residual colorectal tumors after EGFR blockade are made of slowly cycling cells that resemble 
EGFR-inhibited normal intestinal cells 
For population-level assessment of residual disease after cetuximab therapy we deployed a series of 
279 mCRC PDXs, derived from as many patients, part of which had been used in previous independent 
studies (16,20,21). Tumor regressions for analysis of residual disease (designated as at least 50% 
mean tumor volume reduction compared with pre-treatment volumes) were scored in 40 cases (14.3%) 
(Fig. 1A). Consistent with observations in patients (15), all these responsive cases were wild-type for 
clinically validated resistance mutations (KRAS, NRAS, and BRAF) (Fig. 1A) and for additional 
alterations that are known to confer resistance or attenuate response (16-21), but have not yet entered 
routine determination. 
Among responsive PDXs, systematic studies for specific biomarkers were conducted on 30 cases 
(hereafter referred to as ‘reference collection’) (Fig. 1A). A variable number of these models were used 
for more complex investigations. In the reference collection, residual disease cells after 6 weeks of 
therapy exhibited widespread reduction (but not complete abrogation) of cell proliferation compared to 
the untreated tumors, together with a slight increase in apoptosis (Fig. 1B). Longitudinal evaluation for 
12 weeks in 2 cases (CRC0078 and CRC0096) revealed a drastic drop in cell proliferation immediately 
after therapy initiation, with later resumption of low but continuous mitotic activity beginning 1 
(CRC0078) or 3 (CRC0096) weeks after treatment onset (fig. S1A). Cell-cycle slowdown after 
prolonged treatment with cetuximab was confirmed by reduction of 5-ethynyl-2’-deoxyuridine (EdU) 
incorporation in both PDXs and organoids (fig. S1B). The number of apoptotic cells fluctuated only 
marginally over time, without an apparent trend (fig. S1A). The fact that tumor shrinkage was 
accompanied by reduced cancer cell proliferation in the absence of more pronounced apoptosis can 
be explained as the result of a new equilibrium imposed by cetuximab-dependent cell-cycle arrest on 
the spontaneous growth and death dynamics of the tumor mass, with a shift in the net balance between 
cell production and cell loss that favored basal tumor attrition without increasing the number of 
apoptotic cells (22). We also monitored response to a long-term stop-and-go schedule of cetuximab in 
1 case. Antibody administration in mice with exponentially growing tumors resulted in a rapid (4 weeks) 
and massive (approximately 80%) plateau of tumor regression, but failed to achieve tumor eradication 
(fig. S1C). Therapy was maintained for additional 17 weeks and then suspended. Upon treatment 
withdrawal, and following a latency of 5 weeks, tumors started regrowing with kinetics and phenotypes 
similar to treatment-naïve counterparts, and were sensitive to antibody rechallenge (fig. S1C).  
To explore whether the residual cells that persist at maximal response originate from genetic 
selection or stochastic plasticity, we reasoned that if cetuximab favored the outgrowth of genetically 
defined pre-existing subclones, a population bottleneck would arise with an enrichment of high-
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frequency somatic mutations (fig. S2A); conversely, a lack of substantial modifications in the frequency 
distribution of sequence variants would be compatible with functional plasticity (fig. S2B). Whole-
exome sequencing (WES) in 2 models of the reference collection did not reveal an enrichment for 
somatic mutations either in cetuximab-treated samples or in tumors that had relapsed following drug 
withdrawal, when compared to untreated tumors (fig. S2, C and D). Since our survey was restricted to 
protein-coding genes, we cannot formally exclude therapy-induced changes in the mutational profile 
of DNA regulatory regions. However, our results suggest that cetuximab pressure does not cause a 
measurable expansion of subclonal populations; rather, residual cancer cells likely undergo plastic 
phenotypic changes in the absence of substantial genetic selection. To achieve higher resolution, we 
also investigated whether rare subclones harboring known cetuximab resistance mutations had 
emerged during prolonged antibody treatment in 5 PDX models. Sequenom genotyping for hotspot 
mutations in 9 genes and Nanostring evaluation of copy number alterations in 11 genes documented 
a wild-type euploid or nearly euploid status for established resistance-associated genotypes in residual 
tumors after therapy (data file S1). A hitherto unrecognized Y1021S mutation in the PIK3CA gene, with 
no demonstrated connection to cetuximab resistance, was present at a 10% allele frequency in 1 of 2 
post-cetuximab samples obtained from 1 model. Collectively, these results indicate that residual 
disease in PDXs has the identifying characteristics of drug tolerance, as observed in cultured cell lines 
(5): smoldering growth and minimal apoptosis under drug pressure; a metastable state of reversible 
sensitivity to therapy; and no acquisition or selection of resistance-conferring genetic alterations.  
To better understand the molecular features of residual disease, we carried out a microarray-
based gene expression analysis in 18 cetuximab-sensitive PDX models (including 12 models from the 
reference collection) and extracted paired information on vehicle- versus cetuximab-treated tumors 
(GSE108277). Combined gene set enrichment analysis (GSEA) and ingenuity pathway analysis (IPA) 
confirmed the observed reduction of cell proliferation in treated tumors, with no evident signs of 
apoptosis, and revealed a metabolic switch from glycolysis to lipid metabolism and oxidative 
phosphorylation (Fig. 1C and data files S2 and S3). This conforms to findings in pancreatic cancer, in 
which reliance on mitochondrial respiration and impaired glycolytic function have been described as 
hallmarks of a subpopulation of quiescent tumor cells that survive extinction of KRAS oncogenic 
signals and are eventually responsible for tumor relapse (23). 
It has been recently demonstrated that normal murine intestinal stem cells undergo a state of 
reversible quiescence after EGFR inhibition (24), similar to the growth disadvantage observed in 
cetuximab-treated tumors. Accordingly, the transcriptional rewiring triggered by EGFR blockade in 
tumors echoed that of EGFR-inhibited normal stem cells (Fig. 1D). Analogies between the two contexts 
also occurred at the functional level. EGFR-inhibited quiescent stem cells of the normal mouse 
intestine display more pronounced Wnt signal strength compared to rapidly cycling cells with active 
EGFR signaling (24). Likewise, the nuclear localization of -catenin (Fig. 1E) and the expression of the 
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canonical Wnt target genes LGR5, LEF1 and ASCL2 (Fig. 1F), all indicative of Wnt activation, were 
generally higher in residual tumors than in vehicle-treated controls of the reference collection. Stronger 
Wnt signaling in drug-tolerant cells was confirmed by ChIP-seq analysis in 2 representative models, in 
which prolonged cetuximab treatment potentiated -catenin binding to DNA targets (Fig. 1G and fig. 
S3). Similarly, TCF/LEF reporter assays in colospheres revealed increased -catenin-dependent 
transcriptional activity over time after EGFR inhibition (Fig. 1H). Time-course experiments in the two 
PDX models treated with cetuximab for 12 weeks documented an increase in the number of cells with 
higher expression and stronger nuclear staining of -catenin starting one (CRC0078) or two 
(CRC0096) weeks after treatment initiation and persisting until therapy was terminated (fig. S4). 
 
Cancer cells that withstand EGFR inhibition are similar to label-retaining secretory precursors 
expressing markers of the Paneth-cell lineage 
The gene expression profile induced by EGFR blockade in normal intestinal stem cells shares many 
traits with that shown basally by slowly cycling, DNA-label-retaining cells (LRCs) (24), a reserve 
population that accounts for tissue regeneration after damage (25). In keeping with the observation 
that cetuximab-tolerant cancer cells are reminiscent of rarely dividing cells in the normal tissue, we 
observed upregulation of 3 typical LRC markers (BMI1, HOPX, LRIG1) (26) in treated tumors of the 
reference collection (Fig. 2A). TERT, another classical LRC marker (26), was instead downregulated 
in EGFR-inhibited tumors (Fig. 2A), consistent with the fact that EGFR blockade decreases TERT 
expression (27).  
LRCs have been identified as secretory precursors that are committed to mature into Paneth cells 
and express some genes of the Paneth-cell lineage (28). Accordingly, analysis of our global 
transcriptomic data revealed that residual PDXs were enriched for a signature of Mex3a-high/Lgr5-
high cells connoting a murine subpopulation of slowly dividing intestinal stem cells with elevated Wnt 
signaling and expression of Paneth cell genes (29) (Fig. 2B). The gene expression profile of residual 
tumors was also enriched for a signature of proper Paneth cells of the mouse small intestine (30) but 
it did not show commonalities with Reg4+ deep crypt secretory cells, which serve as Paneth cell 
equivalents in the murine colon (31) (fig. S5). On this ground, we derived a manually curated gene 
subset that includes established markers of classical Paneth-cell commitment and differentiation, in 
particular, transcription factors that specify the secretory fate of intestinal progenitors (ATOH1, GFI1, 
SOX9, XBP1) and markers of Paneth-cell terminal differentiation (DEFA5, DEFA6, LYZ, SPINK4, 
DLL1, DLL4) (‘secretory/Paneth-cell signature’) (32). By performing GSEA in our microarray dataset, 
we found that this signature was upregulated in cetuximab-treated PDXs (Fig. 2C). For 5 genes with 
strong induction by cetuximab (‘core signature’) (data file S4), results were validated by RT-qPCR in 
the reference collection (Fig. 2D). Finally, overexpression of the top-ranked markers defensin-5 
(DEFA5) and defensin-6 (DEFA6) in residual tumors was substantiated at the protein level, with an 8-
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fold and a 2-fold increase in the average percentage of protein positivity for DEFA5 and DEFA6, 
respectively (Fig. 2E). DEFA5 positivity in treated tumors was almost invariably associated with -
catenin nuclear accumulation (fig. S6), compatible with the gene expression data showing the co-
occurrence of high Wnt signaling and Paneth cell-like pseudodifferentiation in residual tumors. 
To analyze the temporal dynamics of Paneth cell-like phenotypic rewiring, we used two different 
observation time frames and treatment schedules. First, we analyzed the expression of the 
secretory/Paneth cell core signature genes over time in the two models in which cetuximab therapy 
had been prolonged for 12 weeks. Like -catenin (fig. S4), many of the core signature genes were 
upregulated soon after the first dose of cetuximab and continued to be more expressed than in control 
tumors during the whole period of antibody administration (fig. S7A). At the protein level, the 
percentage of DEFA6 positivity increased by three folds after two weeks of treatment and remained 
higher at subsequent time points (fig. S7B). Second, we assessed the expression of the core signature 
genes at an initial time point (after 3 days of treatment) in the whole reference collection and after 
cetuximab suspension (when regrown tumors had reached volumes of around 750 mm3, typically 
several weeks after therapy interruption) in 5 representative cases. Overall, the core signature gene 
transcripts were upregulated as early as 3 days after the first antibody dose – although for some 
transcripts the extent of gene modulation was lower than that detected in long-treated tumors – (fig. 
S7C) and most of them reverted after antibody withdrawal (fig. S7D). Hence, cetuximab induces 
reversible changes that are rapidly acquired after therapy onset, consolidate in residual disease under 
continued drug pressure, and dissipate after therapy discontinuation. Principal component analysis of 
global RNA-seq data from untreated, cetuximab-treated, and regrown samples in 1 PDX model 
confirmed that tumors that had relapsed after therapy discontinuation showed a transcriptomic profile 
indistinguishable from that of their untreated counterparts, but radically different from that of on-
treatment samples (fig. S7E). This reinforces the notion that the phenotypic rewiring experienced by 
residual tumors is driven by cancer cell functional plasticity rather than selection of preexisting resistant 
cells.  
Analysis of the baseline gene expression profiles of our series of therapeutically annotated PDXs 
(n = 241; GSE76402) (33) revealed higher expression of the secretory/Paneth-cell signature genes in 
cetuximab-resistant tumors than in sensitive cases (Fig. 2F). This result holds also when moving to a 
clinical setting; using a publicly available gene expression dataset comprising CRC metastases from 
80 individuals treated with cetuximab monotherapy (GSE5851) (34), we found that patients bearing 
tumors with high expression of the signature genes had shorter PFS than patients with tumors showing 
low signature expression (Fig. 2G). Overall, data in PDXs and in patients suggest that 
secretory/Paneth-cell like traits may be general hallmarks of tolerance to EGFR blockade not only in 
cancer cell persisters after adaptation to antibody treatment, but also in tumors that are poorly sensitive 
ab initio.  
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Acquisition of the Paneth cell-like phenotype in residual cells is regulated by inactivation of 
YAP 
YAP, a downstream transcriptional effector of the Hippo pathway, favors post-injury intestinal 
regeneration by intensifying EGFR pathway activity and transiently suppressing Wnt signaling and 
Paneth cell differentiation in murine stem cells (35). The Wnt-high, Paneth cell-like phenotype 
displayed by drug-tolerant tumors led us to speculate that residual disease could be sustained by 
reduced activation of YAP in EGFR-inhibited cancer cells. We thus compared the gene expression 
profiles of residual mCRC tumors after cetuximab treatment with those of mice with YAP conditional 
deletion in the gut (35). The genes with the greatest extent of transcriptional regulation in YAP-knockout 
mice proved to be highly correlated with the genes most strongly modulated by cetuximab in PDXs 
(Fig. 3A). Furthermore, a ubiquitous signature of YAP-inducible target genes (36) was potently 
downmodulated in cetuximab-treated tumors (Fig. 3B). In accordance with a phenotype of signal 
deactivation, expression and/or nuclear accumulation of YAP were reduced in most residual PDXs of 
the reference collection (Fig. 3C). YAP protein reduction, along with transcriptional downregulation of 
YAP target genes, became visible soon after cetuximab administration and was maintained for several 
weeks until the end of the experiment (fig. S8, A and B); after therapy suspension, YAP 
immunoreactivity returned to pre-treatment positivity (fig. S8C). We confirmed these results using 
cetuximab-sensitive CRC cell lines (DiFi and HCA46). In agreement with PDX data, EGFR blockade 
diminished YAP activity, as demonstrated by reduced YAP-dependent transcriptional activity (Fig. 3D). 
Cetuximab treatment also slightly increased the phosphorylation of two inhibitory serine residues 
involved in YAP cytoplasmic retention and degradation (fig. S9A) and reduced the expression of 
established YAP target genes (fig. S9B). Consistent with the notion that YAP negatively regulates Wnt 
signaling (33), Wnt target genes were upregulated after RNAi-mediated YAP knockdown (fig. S10) and 
were downregulated after transduction of a constitutively active form of YAP (YAP-5SA) or – to a lesser 
extent – after transduction of wild-type YAP (fig. S11). 
Among the upstream regulators of YAP activation, the mitogen-activated protein kinase (MAPK) 
cascade and the PI3K/AKT axis play a prominent role (37-39). Because these signals are typically 
triggered by EGFR (40), we investigated the contribution of either pathway to cetuximab-induced YAP 
inhibition. MEK blockade by selumetinib or trametinib was as potent as EGFR inhibition in abating YAP 
reporter activity (Fig. 3D and fig. S12). However, this effect was not recapitulated by PI3K pathway 
neutralization by dactolisib (targeting all PI3K isoforms and mTOR), buparlisib (targeting all PI3K 
isoforms) or alpelisib (targeting PI3K) (Fig. 3D and fig. S12). Similarly, the modulation of established 
YAP target genes was concordant after EGFR or MEK blockade, whereas it was less profound and/or 
more heterogeneous after PI3K pathway inhibition (fig. S9B). Collectively, these results indicate that 
cetuximab mainly impinges on the MAPK pathway for YAP inactivation. 
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To explore whether cetuximab-dependent YAP inhibition has a role in cancer cell persistence, we 
simulated a therapeutic setting in established cell-line xenografts. In particular, we analyzed tumor 
growth kinetics during doxycycline-regulated expression of constitutively active YAP-5SA (fig. S13, A 
and B) and/or administration of cetuximab, followed by post-treatment monitoring of residual disease 
burden. After 3 weeks of treatment, DiFi tumors with induced expression of active YAP had grown 
slower than the non-induced (YAP-5SA-negative) controls (Fig. 3E). Moreover, after treatment 
withdrawal, tumors from mice previously treated with cetuximab and induced with doxycycline 
experienced markedly stronger growth disadvantage than tumors from mice treated with cetuximab 
only (Fig. 3E). Growth retardation in xenografts expressing YAP-5SA suggests that YAP 
hyperactivation decreases the fitness of EGFR-dependent cells; in drug-tolerant cells surviving 
prolonged treatment with cetuximab, this effect is exacerbated and translates into weakened 
restoration of tumor growth following therapy discontinuation. Thus, YAP inhibition is expected to 
strengthen the viability of EGFR-inhibited cells, instigating cell persistence and contributing to residual 
disease.  
To causally link EGFR blockade, YAP inhibition, and acquisition of the Paneth cell-like phenotype, 
we modulated EGFR pathway and YAP activity in cell lines and patient-derived models. We confirmed 
increased expression of the core signature secretory/Paneth cell genes after EGFR inhibition in cell 
lines and patient-derived cultures, as observed in PDXs (fig. S13C). In analogy with the YAP reporter 
assays, upregulation of such genes was induced by MEK inhibitors but not by agents targeting the 
PI3K pathway, both in vitro and in vivo (Fig. 4A and Fig. S13, D and E). This indicates that cetuximab-
regulated YAP inactivation and induction of the Paneth cell-like phenotype are both primarily mediated 
by inhibition of the MAPK cascade. Congruent with the assumption that YAP suppresses Paneth cell 
pseudodifferentiation in CRC cells, secretory/Paneth cell genes were upregulated after RNAi-mediated 
silencing of YAP (fig. S14A) and some of them were downregulated after exogenous expression of 
constitutively active YAP-5SA (fig. S14B). Notably, enforced YAP-5SA expression prevented 
cetuximab-induced upregulation of secretory/Paneth cell markers (Fig. 4B). A reduction in the basal 
expression of the secretory/Paneth cell genes was also achieved by ectopic overexpression of wild-
type YAP (fig. S14B); however, consistent with the fact that wild-type YAP can still be modulated by 
upstream signals, its ability to blunt the effect of cetuximab on the acquisition of the Paneth cell-like 
phenotype was weaker than that of YAP-5SA (Fig. 4B). Similar to in vitro data, established DiFi 
xenografts had increased expression of secretory/Paneth cell genes after cetuximab treatment and 
decreased expression of the same genes after doxycycline-regulated expression of YAP-5SA (Fig. 4C 
and fig. S14C); moreover, again in accordance with the in vitro results, conditional YAP-5SA induction 
in xenografts attenuated cetuximab-dependent upregulation of the secretory/Paneth cell markers, with 
a particularly pronounced effect for the top-ranked genes DEFA5 and DEFA6 (Fig. 4C). Together, 
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these findings support a causal role for YAP inhibition in mediating the lineage rewiring engendered 
by EGFR blockade, both in vitro and in vivo. 
The pro-regenerative program driven by YAP in the normal intestine entails not only suppression 
of Wnt signaling and Paneth cell differentiation, but also transcriptional induction of EGFR ligands, in 
particular, amphiregulin (AREG), epiregulin (EREG) and heparin-binding EGF (HBEGF) (35). In line 
with this evidence, EGFR-inhibited residual PDXs of the reference collection showed slight but diffuse 
reduction in the quantity of AREG, HBEGF and EGF and marked downregulation of EREG, together 
with overexpression of betacellulin (BTC) (fig. S15). High amounts of AREG and EREG correlate with 
response to EGFR antibodies in mCRC patients (34), whereas BTC can substitute for HER3 ligands 
in activating the HER2/HER3 heterodimer (41,42). Therefore, the drug-tolerant state in CRC is 
characterized by reduced expression of ligands that sustain EGFR dependency and increased 
expression of a growth factor that can activate alternate survival pathways. 
 
Combined EGFR/PI3K inhibition reduces residual disease in vitro but has little impact on tumor 
control in vivo 
Analysis of residual tumors after EGFR inhibition revealed widespread reduction of cell proliferation 
without conspicuous signs of apoptosis (Fig. 1B). Accordingly, cetuximab did not trigger considerable 
apoptosis (as assessed by caspase-3/7 activation) in DiFi and HCA46 cells (fig. S16A). We reasoned 
that one way to chart therapeutic vulnerabilities in residual disease was to pinpoint targets that, when 
co-inhibited together with EGFR, synergistically enhance cell death. EGFR mainly signals via the PI3K-
AKT, MAPK, JAK-STAT, and NF-B pathways (40). When used in monotherapy, specific inhibitors 
against each of these pathways were ineffective (fig. S16A). When combined with cetuximab, the drugs 
with the strongest pro-apoptotic activity were those selectively intercepting the PI3K-AKT signaling axis 
(as evidenced by abrogation of AKT phosphorylation after treatment with representative PI3K 
inhibitors) (Fig. 5A and fig. S16B). Similar to that observed in cell lines, co-inhibition of EGFR and PI3K 
in CRC0078 colospheres exerted more synergistic effects on reducing cell viability than combined 
blockade of EGFR and another target (MEK) (fig. S16C); consistently, although concomitant 
neutralization of EGFR and MEK led to smaller colospheres than cetuximab alone, only co-inhibition 
of EGFR and PI3K almost completely obliterated the colonies (Fig. 5B). We also evaluated the 
colospheres for their latency before resuming proliferation after treatment cessation; cells that had 
survived prolonged treatment with cetuximab alone or cetuximab and the MEK inhibitor selumetinib 
promptly regained growth ability after drug washout; conversely, concomitant blockade of EGFR and 
PI3K prevented regrowth after treatment withdrawal (Fig. 5C).  
The fact that apoptosis was unleashed only when EGFR and PI3K were concomitantly inhibited 
suggests that the antitumor effects of cetuximab are attenuated by persistent activation of the PI3K 
pathway. Indeed, cetuximab treatment almost completely abated extracellular signal-regulated kinase 
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(ERK) phosphorylation in cell lines and colospheres, whereas AKT phosphorylation was only partially 
affected or remained unaltered (fig. S17A). Similarly, in cetuximab-treated PDXs of the reference 
collection, the phosphorylation of ERK was more markedly reduced than that of ribosomal protein S6 
(S6), a downstream effector of PI3K/AKT (fig. S17B); as expected, ERK and S6 phosphorylation was 
regained in tumors that had resumed growth after cetuximab discontinuation (fig. S17C). We note that 
a dichotomy between MAPK and PI3K signaling was also observed when delineating the pathways 
that transduce cetuximab-dependent impairment of YAP activity and upregulation of secretory/Paneth 
cell genes. In that case, MAPK inhibition better recapitulated the effects of cetuximab compared with 
PI3K inhibition (Fig. 3D, Fig. 4A, fig. S9B, fig. S12, fig. S13, D and E). Collectively, these results indicate 
that the outcomes of EGFR inhibition in CRC are largely regulated by inactivation of the MAPK 
pathway, and are countered by enduring PI3K signaling in residual cells. 
Although concomitant inactivation of the EGFR and PI3K pathways increased cancer cell 
apoptosis in vitro, the burden of residual disease was only partially lessened in mice treated with both 
EGFR and PI3K inhibitors with respect to mice treated with cetuximab alone. We used the combination 
of cetuximab and dactolisib versus cetuximab monotherapy in 7 PDX models, all with wild-type forms 
of the PIK3CA and PTEN genes. In 4 such models, we also tested cetuximab and alpelisib as an 
alternative PI3K inhibitor. Both compounds were administered at pharmacodynamically active 
concentrations, as indicated by the specific reduction of phospho-S6 in tumors treated with either 
inhibitor (fig. S18A) and the decrease of both phospho-S6 and phospho-ERK in tumors treated also 
with cetuximab (fig. S18B). When dosed as monotherapies, both dactolisib and alpelisib did not induce 
tumor shrinkage (fig. S18C). The combination of dactolisib and cetuximab proved to be more effective 
than cetuximab alone in regressing palpable masses in 2/7 (28.6%) models, and the combination of 
alpelisib and cetuximab was superior to single-agent cetuximab in 2/4 (50%) cases (Fig. 5D and fig. 
S19). In aggregate, response to cetuximab and either dactolisib or alpelisib was better than response 
to cetuximab alone in 4/7 models (57%), indicating that the effect of dual EGFR-PI3K blockade was 
relatively distributed in the PDX subset tested. However, susceptibility to dactolisib or alpelisib was 
heterogeneous in the models treated with both compounds, likely due to the different targets of the two 
inhibitors (all PI3K isoforms and mTOR in the case of dactolisib versus PI3K only for alpelisib) and 
the different nature of the ensuing signaling feedback loops (43). 
Inspection of cancer cell density in PDXs with no macroscopic response revealed decreased 
representation of epithelial neoplastic islets in 3/5 (60%) tumors, which suggests some therapeutic 
efficacy in a context of preponderant reactive stroma (fig. S20A). Dual inhibition of EGFR and PI3K 
induced a slight increase in the number of apoptotic cells compared with individual EGFR blockade in 
some PDX models in which the combination therapy was more effective than cetuximab alone (Fig. 
5D and S20B). However, deeper tumor shrinkage was not invariably accompanied by heightened 
apoptosis; some tumors with stronger induction of apoptosis after combination therapy did not respond 
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better in terms of tumor regression, and others with a more pronounced size reduction were not more 
apoptotic (Fig. 5D and fig. S20B). Similar to our interpretation of cetuximab-induced tumor regression 
in the absence of overt apoptosis, also in this case tumor shrinkage in models sensitive to the 
combination therapy was probably caused by the strong antiproliferative effect of dual EGFR-PI3K 
inhibition (which shifted the steady-state equilibrium between new cell production and cell loss toward 
tumor breakdown) rather than by apoptosis induction. 
The limited extent of residual disease reduction documented above was not sufficient to increase 
animals’ survival; indeed, PI3K blockade on top of cetuximab did not affect time to relapse after 
treatment discontinuation in the 4 PDX models examined (fig. S20C). In summary, combined EGFR 
and PI3K blockade was more effective than cetuximab alone in impairing cell viability in vitro; however, 
this therapy provided suboptimal and model-specific benefits in reducing residual disease at the end 
of treatment and did not have long-term effects on tumor control after therapy suspension. 
 
Inhibition of the EGFR-YAP axis leads to increased HER2/HER3 signaling in PDXs and in 
patients 
To identify more effective therapies against residual disease in vivo we searched for compensatory 
cues triggered by inhibition of the EGFR-YAP axis and expected to sustain persistent PI3K signaling. 
We focused on HER2 and HER3, prompted by the knowledge that tumor models treated with EGFR 
or PI3K inhibitors experience feedback activation of such receptors and that HER2/HER3 signaling 
preferentially impinges on the PI3K pathway (44-47). We started by gauging HER2 and HER3 
expression in DiFi and HCA46 cells transduced with either a control vector or various YAP constructs, 
in the presence or absence of cetuximab. EGFR blockade resulted in increased expression of HER2 
and HER3 in control cells (Fig. 6A); in a complementary fashion, ectopic introduction of constitutively 
active YAP-5SA lowered the basal amounts of HER2 and/or HER3 (fig. S21A) and blunted their 
upregulation by cetuximab (Fig. 6A). Likewise, doxycycline-regulated activation of YAP in established 
DiFi xenografts reduced the extent of HER2 and HER3 induction prompted by cetuximab (Fig. 6B). 
Similar to that described for YAP-5SA, transduction of wild-type YAP led to a reduction of HER3 basal 
expression (fig. S21B); however, since wild-type YAP can still be inhibited by upstream signals, its 
exogenous overexpression was not sufficient to prevent HER2/HER3 upregulation by cetuximab (fig. 
S21C). In complementary loss-of-function experiments, we found that only the more effective shRNA 
construct against YAP caused HER3 upregulation while HER2 was downregulated (fig. S21D), 
possibly because YAP depletion unleashed a compensatory activity by its paralog TAZ. In summary, 
the surge in HER2/HER3 expression triggered by EGFR inhibition was prevented by hyperactive YAP 
but it was not phenocopied by YAP silencing, suggesting that YAP is necessary but not sufficient for 
EGFR-dependent modulation of HER2 and HER3. The observation that HER2 and HER3 can be 
transcriptionally modulated by YAP activity is in accordance with the presence of binding site peaks 
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for TEAD4 (a canonical transcriptional partner of YAP and TAZ) in HER2 and HER3 regulatory regions, 
as shown by analysis of the ENCODE ChIP-seq datasets (48).  
We then analyzed HER2 and HER3 expression in treatment-naïve and cetuximab-treated PDXs 
of the reference collection. Consistent with results in cultured cell lines and cell-line xenografts, we 
detected moderate to strong overexpression of HER2 and HER3 in a sizeable fraction of EGFR-
inhibited models (Fig. 6C). Similar to that reported for Paneth cell genes, HER2/HER3 upregulation 
was evident as early as one week after the first cetuximab administration and was maintained for 12 
weeks under antibody treatment (fig. S22). In situ inspection of tissue sections revealed cytoplasmic 
expression of DEFA5 in some, but not all, phospho-HER2 and phospho-HER3-positive cells (fig. S23), 
suggesting that HER2/HER3 activation after cetuximab treatment is regulated by YAP-dependent but 
also YAP-independent pathways. For example, HER2/HER3 could be activated in “bystander” DEFA5-
negative cells due to the observed surge in BTC expression after cetuximab treatment (fig. S15).  
Of note, the transcriptional rewiring occurring in EGFR-inhibited cell lines and PDXs was also 
observed in tumors from patients. The present standard of care for KRAS/NRAS-wild-type mCRC is 
combinatorial treatment with cetuximab/panitumumab and chemotherapy (14,15). Although this 
regimen is typically administered in the chemorefractory setting, with EGFR antibodies having a 
preponderant effect over chemotherapy, residual reactions to cytotoxic agents may influence response 
to EGFR inhibition. To overcome this hurdle, we interrogated samples from patients with 
KRAS/NRAS/BRAF wild-type tumors who had undergone single-agent therapy with Sym004, a mixture 
of two recombinant antibodies against EGFR that induces clinically meaningful rates of tumor 
shrinkage in mCRC patients with acquired resistance to cetuximab or panitumumab (49). Patients had 
been monitored in the frame of a controlled clinical trial with planned on-treatment biopsies right before 
first tumor restaging, with paired tumor tissues including the treatment-naïve surgical specimen after 
primary tumor resection and the on-treatment biopsy of a metastasis, after 4 weeks of therapy. We 
detected strong transcriptional induction of HER2 and HER3 in the on-treatment samples of 2 
individuals who had experienced a RECIST partial response (-38%; patient MPP192-5) or a minor 
tumor shrinkage (-15%; patient MPP192-1) at the time of metastatic biopsy (Fig. 6D). In patient 
MPP192-5, who had responded better to Sym004, we also observed transcriptional upregulation of 
the secretory/Paneth-cell markers DEFA5 and ATOH1 (Fig. 6D) and confirmed DEFA5 overexpression 
at the protein level (Fig. 6E). Such modulations appeared to be specific to sensitive cases, as the 
transcripts were not upregulated in samples from 2 patients in whom Sym004 had been poorly active 
(+6.4%; patient MPP192-2) or ineffective (+37.8%; patient MPP192-4) (Fig. 6D). 
 The notion that EGFR-inhibited tumors experience an adaptive shift from a status of high EGFR 
pathway activity to a condition of enhanced stimulation of HER2/HER3-dependent signals is 
strengthened by the observation that residual PDXs not only showed HER2 and HER3 upregulation, 
but also higher expression of the promiscuous HER ligand BTC (fig. S15). When we modeled this 
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context in cell lines, we found that CRC cells exposed to BTC had stronger activation of EGFR, HER2, 
and HER3, as well as increased phosphorylation of downstream transducers (Fig. 6F). BTC-stimulated 
cells were also less responsive (or totally refractory, in the case of DiFi) to cetuximab (Fig. 6G), 
suggesting that BTC counteracts EGFR blockade through compensatory HER2/HER3 activation. To 
test this hypothesis, we incubated cells with BTC and treated them with Pan-HER, a mixture of 6 
antibodies against the 3 HER receptors (50) (for stoichiometric targeting of EGFR, the Pan-HER 
dosage was adjusted to achieve equimolar concentrations of cetuximab and the anti-EGFR constituent 
of Pan-HER). Different from cetuximab, Pan-HER was effective in reducing the viability of BTC-treated 
cells (Fig. 6G), supporting the notion that HER2, HER3 and BTC restrain responsiveness to individual 
EGFR blockade and impart a new signal dependency to EGFR-inhibited cells. Selective inhibition of 
HER2 or HER3 with trastuzumab or the isolated anti-HER components of Pan-HER did not affect cell 
viability either in the presence or in the absence of BTC, indicating that full co-targeting of HER 
receptors is required to thwart BTC-dependent survival signals (fig. S24). In agreement with increased 
HER2/HER3 pathway activity in vitro, residual tumors in PDXs of the reference collection displayed 
increased phosphorylation of HER2 and HER3 (Fig. 6H). 
 
Targeting HER2/HER3 together with EGFR provides long-term therapeutic benefits in PDX trials 
To explore whether compensatory HER2/HER3 signaling contributes to residual disease in vivo, we 
treated 6 PDX models with cetuximab or Pan-HER. In the 4 PDXs in which cetuximab caused clear 
regressions, the extent of tumor shrinkage obtained with Pan-HER was similar to that achieved by 
cetuximab (Fig. 7A). However, resumption of tumor growth after antibody withdrawal was delayed in 
3/4 (75%) models treated with Pan-HER compared with those treated with cetuximab (Fig. 7B). In 2 
models in which cetuximab left a higher burden of residual disease, Pan-HER was much more effective 
in reducing tumor volumes (Fig. 7C) and, again, in retarding tumor relapse after treatment suspension 
(Fig. 7D). In total, out of 6 PDX cases tested, mouse cohorts implanted with 5 models (83%) 
experienced a survival benefit after therapy cessation.  
The prominent activity of Pan-HER was also evident at the signaling level. Consistent with the 
notion that HER2 and HER3 cooperate for preferential stimulation of the PI3K-AKT pathway, Pan-HER 
induced stronger inhibition of PI3K-dependent signals than cetuximab – as assessed by S6 
phosphorylation – whereas the effects on the MAPK cascade were similar (Fig. 7E and fig. S25). 
Moreover, Pan-HER impeded the feedback activation of HER2 and HER3 triggered by individual EGFR 
blockade (Fig. 7E). In summary, Pan-HER minimized residual disease and reduced EGFR downstream 
signaling in EGFR-dependent mCRC PDXs. This effect translated into tumor control after therapy 





Following EGFR blockade, actively dividing stem cells of the normal mouse intestine morph into 
quiescent cells that maintain robust Wnt signaling and share attributes with DNA-label-retaining 
precursors expressing some secretory markers of the Paneth-cell lineage (24,28,29). Using paired 
samples of untreated and cetuximab-treated PDXs, here we show that EGFR inhibition in mCRC 
tumors results in the emergence of residual cancer cell subpopulations that display hyperactive Wnt 
signaling and express traits of secretory commitment and Paneth cell-like differentiation. Hence, a 
functional reprogramming that drives quiescence of normal intestinal cells in the mouse is resurrected 
during acquisition of drug tolerance in human CRC tumors, suggesting a higher-order lineage plasticity 
that goes beyond species and tissue functional state.  
We provide evidence that the Paneth cell-like phenotypic rewiring prompted by EGFR inhibition 
in colorectal tumors is an effect of YAP inactivation. During intestinal regeneration after injury, YAP 
reprograms intestinal stem cells by transiently suppressing Paneth cell differentiation, while bolstering 
EGFR-dependent proliferation mediated by increased production of EGFR ligands (35). In a reciprocal 
scenario, we found that residual tumors after EGFR inhibition had reduced expression and nuclear 
localization of YAP, increased expression of Paneth-cell markers, and downregulation of EGFR-
activating ligands. These features are likely to be causally linked, as exogenous introduction of a 
hyperactive form of YAP prevented the induction of the Paneth cell-like phenotype by cetuximab in 
CRC cell lines. As a further piece of information, we demonstrate here that EGFR activation is not only 
a consequence of YAP function, but also an upstream regulatory event. This module speaks for a 
bistable, feed-forward autoregulatory loop that potentiates EGFR activation when the kinase is not 
constrained, but precipitates EGFR neutralization and fosters evasion from EGFR dependence as 
soon as the receptor activity is restricted, for example by low ligand availability or by pharmacological 
inhibition.  
Many cetuximab-treated tumors also featured HER2 and HER3 overexpression, which, similar to 
manifestation of the Paneth cell-like phenotype, can be ascribed to cetuximab-induced inhibition of 
YAP. YAP inactivation appears therefore to orchestrate both a lineage shift toward the 
secretory/Paneth cell-like fate and a signaling shift from high EGFR activity to high HER2/HER3 
activity. We assume that EGFR pathway rewiring sustains residual disease, as shown by the fact that 
cumulative targeting of EGFR, HER2 and HER3 induced more pronounced tumor regressions and 
delayed tumor relapse after treatment cessation in several PDX models; in this context, we interpret 
the materialization of Paneth-cell-like characteristics as the accompanying phenotype of the change in 
signal dependency, which likely reflects the conserved memory of an in-built program that controls 
differentiation-associated quiescence in the normal intestine and residual disease in tumors. We 
detected HER2/HER3 phosphorylation/activation also in non-Paneth-like (DEFA5-negative) residual 
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cells; this suggests that EGFR family adaptive reprogramming after EGFR inhibition may be enacted 
through additional cooperative mechanisms, for example through BTC upregulation or YAP-
independent, MYC-dependent modulation of HER3 expression (51). HER2/HER3 activation, besides 
driving tolerance in cetuximab-sensitive tumors as a consequence of compensatory gene 
overexpression, may also sustain upfront antibody resistance on a genetic basis, as shown for mCRC 
subsets with ERBB2 gene amplification or mutations (16,19,20). Finally, residual disease may be 
further fostered by implementation of a cancer stem cell program, as we have shown that both EGFR 
inhibition and YAP inactivation led to increased expression of Wnt target genes known to control stem 
cell maintenance in the normal intestine and colorectal cancer (25). 
When translated to the clinic, our results advocate agents targeting functional dependencies in 
residual disease be given as upfront therapies or as sequential therapies immediately after maximal 
response. Such treatments may complement other preemptive strategies aimed to neutralize genetic 
mechanisms of resistance before clinical manifestation of disease progression, for example by 
combining EGFR antibodies and MEK inhibitors for contrasting the outgrowth of RAS-mutant 
subclones (52). Approaches of this kind would be a paradigm shift in clinical decision making by 
repositioning rational therapeutic intervention from the refractory state, when multiple and 
preponderant genetic mechanisms of resistance reduce the chances of clinical benefit, to the phase of 
massive regression. 
We are aware that our findings have certain limitations. For example, we have not tested whether 
Paneth cell-like cells act as tumor-(re)initiating cells following cetuximab cessation, mainly because 
PDXs are hardly amenable to lineage-tracing approaches. Moreover, we acknowledge that the clinical 
validation of our results is restricted to a small number of patients. The procurement of paired pre- and 
on-treatment samples to investigate early adaptive response to therapy remains a hurdle in mCRC, 
not only for ethical and logistical reasons but also owing to the difficulty of selecting patients with a 
treatment history and a clinical monitoring that allow for unequivocal interpretation of the results. For 
accurate clinical investigation of residual disease we decided to interrogate samples from mCRC 
patients who had received a ‘clean’ treatment (EGFR antibody monotherapy without concomitant 
chemotherapeutic agents), even though this conservative choice limited the analysis to 4 patients. 
Albeit circumscribed to a small cohort of individuals, the results confirmed HER2 and HER3 
upregulation in the residual tumors of sensitive patients and overexpression of secretory/Paneth-cell 
markers in 1 good responder. The clinical relevance of our findings is also backed by evidence that 
patients experiencing earlier relapse during cetuximab therapy had tumors with higher amounts of 
secretory/Paneth cell markers than individuals with longer PFS, providing clinical support to the notion 
that this cell fate reprogramming typifies lingering cells that tend to endure EGFR inhibition.  
Transdifferentiation has been associated with drug resistance in NSCLC, prostate cancer, and 
melanoma (9,53,54). By extending the generality of this mechanism to other tumor types, our results 
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illustrate how perturbations of conserved developmental pathways that control cellular plasticity may 
represent key factors for shaping drug response in cancer, and motivate the design of therapeutic 
strategies to target the reversible phase of drug tolerance preceding the onset of mutational resistance. 
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MATERIALS AND METHODS 
 
Study design 
This study was designed to identify mechanisms that sustain drug tolerance in residual CRC tumors 
at maximal response to the EGFR antibody cetuximab and find therapies that, when combined with 
EGFR blockade, may minimize residual disease and delay tumor regrowth after treatment 
discontinuation. In the first part of the study, cohorts of nonobese diabetic-severe combined 
immunodeficient (NOD-SCID) mice bearing tumors expanded from 279 independent PDXs (12 or 24 
mice for each original sample) were treated with cetuximab monotherapy to identify cases with 
objective but incomplete response. In the second part, molecular profiles (gene expression data 
obtained from oligonucleotide microarrays and/or RT-qPCR) were analyzed to extract the identifying 
features of residual disease and put forward hypotheses about potential regulatory mechanisms. In 
the third part, mechanistic studies based on the working hypotheses emerged from the second part 
were conducted using forward and reverse genetics in cell lines. Finally, candidate targets likely to 
sustain residual disease were inhibited with specific therapies, alone or in combination with cetuximab, 
in PDXs. Tumor-bearing mice were randomized to treatment cohorts. Cohort sample sizes were 
calculated to have 80% power to detect a twofold change in tumor size between groups, using a two-
group t test with a two-sided type I error rate of 0.05. End points for animal experiments were selected 
in accordance with institutional-approved criteria and guidelines from the Italian National Institute of 
Health. Information on immunohistochemistry and morphometric quantitations, molecular and 
bioinformatics analyses, and cell-based experimentation can be found in the Supplementary Materials. 
Details regarding sample number and replication in assays, as well as statistical analysis, are given in 
figure legends and in the Methods below. All values for quantitation of immunohistochemistry images 
and tumor growth curves in animal experiments were recorded blindly. 
 
Specimen collection and annotation 
Tumor and matched normal samples were obtained from patients treated by liver metastasectomy at 
the Candiolo Cancer Institute (Candiolo, Torino, Italy), Mauriziano Umberto I (Torino), and San 
Giovanni Battista (Torino). All patients provided informed consent. Samples were procured and the 
study was conducted under the approval of the Review Boards of the Institutions.  
 
PDX models and in vivo treatments 
Tumor implantation and expansion were performed in 6-week-old male and female NOD/SCID mice 
as previously described (16). Once tumors reached an average volume of ~400 mm3, mice were 
randomized into treatment arms, with at least n = 5 per group, and were treated with the modalities 
indicated in the figures. Dactolisib (Carbosynth) was dissolved in 1 volume of N-methyl-2-pyrrolidone 
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(Sigma Aldrich) and 9 volumes of PEG300 (Fluka). Alpelisib (Carbosynth) was dissolved in 0.5% 
carboxymethylcellulose (Fluka). Doxycycline was dissolved in water. Tumor size was evaluated once-
weekly by caliper measurements, and the approximate volume of the mass was calculated using the 
formula 4/3  (d/2)2 . D/2, where d and D are the minor tumor axis and the major tumor axis, 
respectively. Results were considered interpretable when a minimum of 4 mice per treatment group 
reached the pre-specified endpoints (at least 3 weeks on therapy or development of tumors with 
average volumes larger than 1500 mm3 within each treatment group in trials aimed to assess drug 
efficacy; at least 3 weeks after treatment cessation or development of individual tumors with volumes 
larger than 750 mm3 in survival experiments aimed to assess tumor control by therapy). Operators 
were blinded during measurements. In vivo procedures and related biobanking data were managed 
using the Laboratory Assistant Suite (55). Animal procedures were approved by the Italian Ministry of 
Health (authorization 806/2016-PR). 
 
Statistics 
Error bars indicate standard deviations (SD) unless otherwise indicated. The number of biological 
(nontechnical) replicates for each experiment is reported in the figure legends. For experiments with 
two groups, statistical analysis was performed using two-tailed Student’s t-test, Welch’s t-test or 
Wilcoxon matched pairs signed-rank test unless otherwise noted. For experiments with more than two 
groups, one-way ANOVA was used. Two-way ANOVA was applied for experiments in which the 
determinations were considered interdependent. In case of multiple testing, we adopted the Benjamini, 
Krieger and Yekutieli false discovery rate (FDR) two-stage step-up method or the Benjamini-Hochberg 
FDR test. Correlations were calculated by Pearson’s coefficients. Statistical analyses in the survival 
experiments were performed by Log-rank (Mantel-Cox) test. The level of statistical significance was 
set at P < 0.05. For multiple comparisons, the results were considered significant when the Benjamini, 
Krieger and Yekutieli method was < 0.05 and when the Benjamini–Hochberg FDR was < 0.1. Graphs 
were generated and statistical analyses performed using the GraphPad Prism (v8.0) statistical 





Materials and Methods 
 
Figure S1. Biological characterization of residual disease after prolonged treatment with cetuximab in 
representative mCRC PDXs 
 
Figure S2. Analysis of adaptive changes versus clonal selection induced by cetuximab in 
representative mCRC PDXs 
 
Figure S3. ChIP-seq analysis of residual disease after prolonged treatment with cetuximab in 
representative mCRC PDXs 
 
Figure S4. Longitudinal analysis of -catenin expression at different time points during prolonged 
treatment with cetuximab in representative mCRC PDXs 
 
Figure S5. GSEA of residual PDXs with signatures of Paneth cells and deep secretory cells  
 
Figure S6. DEFA5 and -catenin double staining in representative mCRC PDXs treated with cetuximab 
 
Figure S7. Transcript and protein changes of Paneth-cell markers and global gene expression 
variations in representative mCRC PDXs during different time points of cetuximab treatment and after 
therapy suspension 
 
Figure S8. Expression of YAP and YAP targets in representative mCRC PDXs during different time 
points of cetuximab treatment and after therapy suspension 
 
Figure S9. Inhibition of YAP activity and expression of YAP-dependent genes by cetuximab in CRC 
cell lines 
 
Figure S10. Expression of secretory/Paneth cell genes after YAP silencing in CRC cell lines 
 
Figure S11. YAP-dependent regulation of Wnt target genes in CRC cell lines 
 
Figure S11. Expression of secretory/Paneth cell genes after YAP silencing in CRC cell lines. 
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Figure S12. Modulation of YAP transcriptional activity by cetuximab and other inhibitors of the EGFR 
pathway in CRC cell lines 
 
Figure S13. Expression/activity of doxycycline-inducible YAP-5SA and modulation of secretory/Paneth 
cell genes by EGFR pathway inhibition in vitro and in vivo 
 
Figure S14. Expression of secretory/Paneth cell genes after YAP silencing or YAP overexpression in 
vitro and in vivo 
 
Figure S15. Modulation of EGFR family ligands in mCRC PDXs treated with cetuximab 
 
Figure S16. Effects of individual signal inhibition and dual blockade of EGFR and PI3K or EGFR and 
MEK in CRC cell cultures 
 
Figure S17. Effects of cetuximab on downstream signals in vitro and in vivo 
 
Figure S18. Effects of PI3K inhibitors on downstream signals and tumor growth in vivo 
 
Figure S19. Effects of PI3K inhibition and combined EGFR and PI3K inhibition on mCRC PDX 
macroscopic residual disease (pre-treatment and end-of-treatment tumor volumes) 
 
Figure S20. Effects of combined EGFR and PI3K inhibition on mCRC PDX microscopic residual 
disease, apoptosis, and survival 
 
Figure S21. YAP-dependent transcriptional modulation of HER2 and HER3 in CRC cell lines 
 
Figure S22. Modulation of HER2 and HER3 expression in mCRC PDXs during prolonged treatment 
with cetuximab 
 
Figure S23. DEFA5 and HER2/HER3 double staining in representative mCRC PDXs treated with 
cetuximab 
 
Figure S24. CRC cell line sensitivity to individual targeting of HER family members 
 
Figure S25. Effects of cetuximab and Pan-HER on EGFR downstream targets in vivo 
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Data file S2 (Microsoft Excel format). GSEA of gene expression changes induced by cetuximab in 
mCRC PDXs 
 
Data file S3 (Microsoft Excel format). Ingenuity pathway analysis of gene expression changes induced 
by cetuximab in mCRC PDXs 
 
Data file S4 (Microsoft Excel format). Expression changes of secretory/Paneth cell genes induced by 
cetuximab in the reference collection (GSE108277) 
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Figure 1. Residual tumors after EGFR blockade are made of slowly cycling cells with high Wnt 
signaling 
(A) Waterfall plot of response after 3 weeks of treatment with cetuximab (20 mg/kg twice a week), 
compared with tumor volume at baseline, in a population of 279 PDX models (n = 6 or 12 mice for each 
bar, depending on whether initial engraftment was successful in one or two mice). Dotted lines indicate 
the cut-off values for arbitrarily defined categories of therapy response (14): regressions (below the 
lower line, -50%), progressive disease (above the upper line, +35%), and stabilizations (between the 
lines). Gray bars designate cases with no mutations in KRAS, NRAS, or BRAF; red, orange, and yellow 
bars denote cases harboring the indicated mutations. Green bars identify the ‘reference collection’ of 
responder cases selected for characterization of residual disease (all wild-type for KRAS, NRAS, and 
BRAF). (B) Morphometric quantitation of proliferation (Ki67 staining, left panel) and apoptosis (caspase 
3 staining, right panel) in PDXs from the reference collection after treatment with vehicle (until tumors 
reached an average volume of 1500 mm3) or cetuximab (for 6 weeks). Each dot represents the average 
of 10 optical fields (Ki67, 40X) or 5 optical fields (caspase 3, 20X) in a section from randomly chosen 
tumors from vehicle-treated and cetuximab-treated mice bearing a PDX from the same original patient 
(n = 30). The plots show means ± SD. Statistical analysis by two-tailed paired Student’s t-test. Casp, 
caspase. Cetux, cetuximab. (C) Scatter plot showing GSEA (diamonds) and IPA (circles) results of 
differential gene expression profiles obtained by comparing PDXs treated with cetuximab with their 
matched vehicle-treated controls (GSE108277). Enrichments are plotted on the y axis, and their 
significance is plotted on the x axis. Relevant gene sets related to cell cycle and metabolism are colored 
as shown in the figure. ES, enrichment score. (D) GSEA plots showing modulation of the EGFR 
inhibition signature, as observed in LGR5+ normal intestinal cells (23), in PDXs treated with cetuximab 
(GSE108277). EGFRi, EGFR inhibition; NES, normalized enrichment score; FDR, false discovery rate. 
(E) Left panel, qualitative morphometric assessment of the extent of nuclear -catenin translocation in 
PDXs from the reference collection after treatment with cetuximab for 6 weeks, compared with vehicle-
treated counterparts. Right panels, representative images in PDXs from the reference collection after 
treatment with vehicle or cetuximab. Scale bar, 50 m. (F) Heatmap showing expression changes for 
the indicated Wnt target genes in PDXs of the reference collection after treatment with cetuximab for 
6 weeks, as assessed by RT-qPCR. Average gene expression, Log2R relative to vehicle-treated 
tumors: LGR5 0.46, P = 0.029; LEF1 1.98, P < 0.0001; ASCL2 0.61, P = 0.011 by two-tailed Wilcoxon 
test. Benjamini-Hochberg FDR < 0.1 for all genes. (G) Heat maps of CTNNB1 gene (encoding -
catenin) ChIP-seq signal in the indicated tumors and experimental conditions at CTNNB1 enriched 
genomic loci +/-4kb to the peak center. (H) Longitudinal time-lapse monitoring of -catenin 
transcriptional activity in CRC0078 colospheres transduced with a TOP-GFP lentiviral construct 
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containing a TCF/LEF-responsive promoter. PuraMatrix-embedded colospheres were treated with 
vehicle or cetuximab (20 g/ml) in EGF-deprived medium (EGF = 0.4 ng/ml) for 6 days. Upper panel, 
representative images (scale bar, 50 m); lower panel, morphometric quantitation of GFP 
fluorescence. Values are the means ± SEM from one experiment (n = 18 for vehicle-treated 
colospheres and 20 for cetuximab-treated colospheres). Statistical analysis by two-way ANOVA.  
 
Figure 2. Cancer cells that withstand EGFR inhibition express markers of the Paneth cell lineage  
(A) Heatmap showing expression changes for the indicated LRC markers in PDXs of the reference 
collection after treatment with cetuximab (20 mg/kg twice a week for 6 weeks), as assessed by RT-
qPCR. Average gene expression, Log2R relative to vehicle-treated tumors: BMI1 0.57, P = 0.0002; 
HOPX 1.41, P < 0.0001; LRIG1 0.42, P = 0.006; TERT -1.41, P = 0.0071 by two-tailed Wilcoxon test. 
Benjamini-Hochberg FDR < 0.1 for all genes. (B) GSEA plot showing positive modulation of the Mex3a-
high/Lgr5-high signature (29) in PDXs treated with cetuximab (GSE108277). NES, normalized 
enrichment score; FDR, false discovery rate. (C) GSEA plot showing upregulation of a manually 
curated subset of secretory/Paneth cell genes in PDXs treated with cetuximab (GSE108277). (D) 
Heatmap showing expression changes for the indicated secretory/Paneth-cell markers in PDXs of the 
reference collection after treatment with cetuximab, as assessed by RT-qPCR. Average gene 
expression, Log2R relative to vehicle-treated tumors: DEFA5 4.03, P < 0.0001; DLL1 1.12, P = 0.002; 
ATOH1 1.26, P < 0.0001; DEFA6 2.95, P = 0.0001; GFI1 1.04, P = 0.0006 by two-tailed Wilcoxon test. 
Benjamini-Hochberg FDR < 0.1 for all genes. (E) Morphometric quantitation of DEFA5 and DEFA6 
protein expression changes in PDXs of the reference collection after treatment with cetuximab. Each 
bar represents the change of average protein expression in 5 optical fields (20X) in a section from 
randomly chosen tumors from cetuximab-treated mice compared with a tumor from matched vehicle-
treated mice (n = 5 for each bar). Representative images are also shown. P = 0.028 for DEFA5 and 
0.0131 for DEFA6 by two-tailed paired Student’s t-test. Scale bar, 100 m. Cetux, cetuximab. (F) 
Expression of secretory/Paneth cell markers in a dataset of mCRC PDXs annotated for response to 
cetuximab (GSE76402). Each dot represents the average expression of the secretory/Paneth cell 
signature metagene (ATOH1, GFI1, SOX9, XBP1, DEFA5, DEFA6, LYZ, SPINK4, DLL1, DLL4) in 
individual tumors. Log2R relative to the dataset median (red line). P < 0.0001 by two-tailed unpaired 
Student’s t-test. (G) Progression-free survival of patients with CRC metastases treated with cetuximab 
monotherapy (34), divided into two groups using the median signal intensity of the secretory/Paneth 
cell signature metagene as a cutoff (n = 40 patients with high signature and 40 patients with low 
signature). Statistical analysis by Cox regression.  
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Figure 3. Cetuximab inactivates YAP 
(A) Correlation between gene expression changes induced by cetuximab (20 mg/kg twice a week for 
6 weeks) in CRC PDXs and those induced by YAP knock-out (YAP/) in the normal mouse intestine 
(35). Left panel, scatter plot of gene expression changes. Right panel, Pearson’s correlation of 
differentially regulated genes. Cetux, cetuximab. (B) GSEA plot showing the regulation of YAP-
inducible target genes (36) in PDXs treated with cetuximab. NES, normalized enrichment score; FDR, 
false discovery rate. (C) Left panels, qualitative morphometric assessment of YAP total and nuclear 
expression in PDXs from the reference collection after treatment with cetuximab, compared with 
vehicle-treated counterparts. Right panels, representative images in PDXs from the reference 
collection after treatment with vehicle (until tumors reached an average volume of 1500 mm3) or 
cetuximab. Scale bar, 50 m. Expr, expression; ref, reference. (D) Measurement of YAP transcriptional 
activity in DiFi and HCA46 cell lines after treatment for 48h with vehicle (DMSO), cetuximab (20 μg/ml), 
selumetinib (1 μM), or dactolisib (250 nM). Luciferase activity was normalized against reporter plasmid 
concentrations as determined by DNA qPCR and expressed as arbitrary units (A.U.). Three 
independent experiments were performed in biological quadruplicates (n = 12). The plots show means 
± SD. Statistical analysis by one-way ANOVA followed by Benjamini, Krieger and Yekutieli FDR 
correction. (E) Effect of doxycycline-regulated YAP activation, with or without concomitant EGFR 
inhibition, in established DiFi xenografts. Left panel, tumor volume changes after 3 weeks of treatment 
with cetuximab (20 mg/kg, intraperitoneal injection twice a week) and/or doxycycline (50 mg/kg daily 
oral gavage). Right panel, tumor volume changes after 4 weeks from treatment suspension. n = 7 
animals per each treatment arm. Statistical analysis by one-way ANOVA followed by Benjamini, 
Krieger and Yekutieli FDR correction (left panel) or two-tailed Wilcoxon test (right panel). Control, 
doxycycline vehicle + cetuximab vehicle; Doxy, doxycycline; Combo, doxycycline + cetuximab.  
 
Figure 4. Acquisition of the Paneth cell-like phenotype in residual cells is regulated by YAP 
inactivation  
(A) RT-qPCR analysis of the indicated secretory/Paneth-cell markers in DiFi and HCA46 cells and in 
CRC0078 colospheres treated with cetuximab, selumetinib, or dactolisib for 72h. Independent 
experiments (n = 3 for DiFi and CRC0078; n = 4 for HCA46) were performed in technical triplicates. In 
some experiments, controls with untreated cells were repeated. The plots show means ± SD. The 
effects of cetuximab and selumetinib were positively correlated (DiFi, r = 0.857; HCA46, r = 0.963; 
CRC0078, r = 0.984, Pearson’s correlation coefficient), whereas dactolisib-induced transcriptional 
changes tended to negatively correlate with those triggered by cetuximab (DiFi, r = -0.592; HCA46, r 
= -0.104; CRC0078, r = -0.905). Cetux, cetuximab. (B) RT-qPCR analysis of the indicated 
secretory/Paneth-cell genes in DiFi and HCA46 cell lines transduced with a pLVX-control vector 
(mock), the constitutively active YAP variant (YAP-5SA), or wild-type YAP (YAP-WT), and treated with 
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cetuximab (20 μg/ml) for 72h. Independent experiments (n = 3 for HCA46 and n = 4 for DiFi) were 
performed in technical triplicates. In some experiments, controls with untreated cells were repeated. 
The plots show means ± SD. Statistical analysis by one-way ANOVA followed by Benjamini, Krieger 
and Yekutieli FDR correction. Stars next to DEFA5 and DEFA6 gene names indicate loss of basal 
expression in the YAP-5SA experimental group, which prevented statistical comparison against mock 
controls for these genes. In the DiFi YAP-WT group, DEFA5 and DEFA6 expression was above 
detection in one replicate. (C) RT-qPCR analysis of the indicated secretory/Paneth-cell genes in 
established DiFi xenografts transduced with doxycycline-inducible YAP-5SA and treated with 
cetuximab (20 mg/kg, 2 administrations), doxycycline (50 mg/kg daily), or both for 1 week. Four 
samples for each condition were analyzed in technical triplicates. The plots show means ± SD. 
Statistical analysis by one-way ANOVA followed by Benjamini, Krieger and Yekutieli FDR correction. 
Doxy, doxycycline. 
 
Figure 5. Combined EGFR/PI3K inhibition unleashes apoptosis and reduces residual disease 
in vitro but has suboptimal activity in vivo 
(A) Luciferase-based evaluation of apoptosis (assessed by caspase 3/7 activity) in DiFi and HCA46 
cell lines treated for 24h with the indicated drugs at the following concentrations: cetuximab, 20 g/ml; 
BMS345541, ruxolitinib, selumetinib, PLX4720, alpelisib, 1 M; dactolisib, 250 nM; everolimus, 50 nM; 
pictilisib, 100 nM; MK2206, 0.5 M; buparlisib, 0.5 M. To make sure that the different drugs would be 
used at biologically relevant concentrations, we mined a publicly available, large-scale data set 
reporting the sensitivity of several hundred cancer cell lines to hundreds of drugs (59); we then 
extracted the minimum IC50 of the specific inhibitors, and used them at an at least two-fold higher 
concentration. The elected drug concentrations have proven to be active in various cell lines also in 
independent studies: (60) (ruxolitinib, alpelisib, pictilisib, buparlisib, MK2206); (61) (dactolisib, 
selumetinib); (62) (everolimus); (63) (PLX4720); and (64) (BMS345541). Results represent the means 
± SD of 2 independent experiments performed in biological quintuplicates (n = 10). The effect of 
different PI3K/AKT inhibitors is indicated by red bars. The targets of each drug are specified. Statistical 
analysis (combinatorial treatment versus cetuximab alone) by one-way ANOVA followed by Benjamini, 
Krieger and Yekutieli FDR correction. Cetux, cetuximab. (B) Representative confocal images of 
PuraMatrix-embedded CRC0078 colospheres treated for 2 weeks with vehicle (DMSO), cetuximab (10 
μg/ml), selumetinib (300 nM), or dactolisib (100 nM), alone or in combination, prior to fixation and 
staining for F-actin (green) and DNA (blue). (C) Growth curves of PuraMatrix-embedded CRC0078 
colospheres treated with cetuximab (30 μg/ml), selumetinib (1 μM), or dactolisib (300 nM), alone or in 
combination, for 21 days and then kept without drugs for additional 28 days. Time-lapse imaging was 
carried out by bright field microscopy, and individual equatorial areas were measured by Image J 
software. Average time-dependent area variation is represented as fold change relative to area value 
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at day 21. Results are the means ± SEM of at least 15 colospheres for each experimental condition. 
Statistical analysis by two-way ANOVA (calculated after drug withdrawal) followed by Benjamini, 
Krieger and Yekutieli FDR correction: cetuximab + selumetinib versus cetuximab alone, P = 0.0138; 
cetuximab + dactolisib versus cetuximab alone, P < 0.0001. (D) Tumor volume changes in PDXs 
treated with the indicated modalities for 4 weeks. Cetuximab, 20 mg/Kg (intraperitoneal injection twice 
a week); dactolisib, 35 mg/Kg (daily oral gavage); alpelisib, 25 mg/Kg (daily oral gavage). Dots 
represent volume changes of individual mice, and plots show the means ± SD for each treatment arm. 
n = 4 to 14 animals per each treatment arm. For CRC0069, CRC0096, CRC0252, CRC0322, 
CRC0542, and CRC0743, statistical analysis was performed by two-tailed unpaired Welch’s t-test. For 
CRC0078, statistical analysis was performed by one-way ANOVA followed by Benjamini, Krieger and 
Yekutieli FDR correction. Tumor variation outliers were excluded using the ROUT method (GraphPad 
Prism). Pre- and end-of-treatment tumor volumes in individual mice are reported in fig. S19.  
 
Figure 6. EGFR blockade leads to increased HER2/HER3 signaling in PDXs and in patients 
(A) RT-qPCR analysis of HER2 and HER3 expression in DiFi and HCA46 cell lines transduced with 
either a pLVX-control vector (mock) or the constitutively active YAP variant (YAP-5SA) and treated 
with cetuximab (20 μg/ml) for 48h. Independent experiments (n = 4 for DiFi and n = 3 for HCA46) were 
performed in technical triplicates. The plots show means ± SD. Statistical analysis by one-way ANOVA 
followed by Benjamini, Krieger and Yekutieli FDR correction. (B) RT-qPCR analysis of HER2 and 
HER3 expression in established DiFi xenografts transduced with doxycycline-inducible YAP-5SA and 
treated with cetuximab (20 mg/kg, 1 administration), doxycycline (50 mg/kg daily), or both for 1 week. 
Four samples for each condition were analyzed in technical triplicates. The plots show means ± SD. 
Statistical analysis by one-way ANOVA followed by Benjamini, Krieger and Yekutieli FDR correction. 
Cetux, cetuximab; Doxy, doxycycline. (C) Heatmap showing expression changes for HER2 and HER3 
in PDXs of the reference collection, after treatment with cetuximab for 6 weeks (20 mg/kg twice a 
week), as assessed by RT-qPCR. Average gene expression, Log2R relative to vehicle-treated tumors: 
HER2 0.29, P = 0.029; HER3 0.31, P = 0.014 by two-tailed Wilcoxon test. Benjamini-Hochberg FDR < 
0.1 for both genes. (D) Heatmap showing expression changes for HER2, HER3, DEFA5 and ATOH1 
in tumors from patients after 4 weeks of treatment with Sym004, as assessed by RT-qPCR. Changes 
in the sum of diameters of target lesions, as per RECIST criteria, are indicated as tumor variations. (E) 
Expression of DEFA5 protein in the treatment-naïve sample and on-treatment biopsy of patient 
MPP192-5. Scale bar, 20 m. IHC, immunohistochemistry (F) Western blot analysis of the indicated 
phosphoproteins in DiFi and HCA46 cells treated for 10 min with BTC at the indicated concentrations. 
Total proteins were used for normalization; vinculin was used as a loading control. Western blots for 
total proteins were run with the same lysates as those used for anti-phosphoprotein detection but on 
different gels. The images shown are representative of 2 experiments on independent biological 
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replicates. P-EGFR, phospho-EGFR; P-HER2, phospho-HER2; P-HER3, phospho-HER3; P-ERK, 
phospho-ERK; P-AKT, phospho-AKT. (G) Quantitation of cell number (assessed by ATP content) in 
DiFi and HCA46 cell lines treated for 72h with the indicated antibodies at the indicated concentrations 
in the absence or presence of 10 ng/ml BTC. Results represent the means ± SD of 2 independent 
experiments performed in biological triplicates (n = 6). Statistical analysis by two-way ANOVA. (H) 
Morphometric quantitation of phospho-HER2 and phospho-HER3 immunoreactivity in PDXs from the 
reference collection after treatment with vehicle (until tumors reached an average volume of 1500 mm3) 
or cetuximab (for 6 weeks). Each dot represents the average of 10 optical fields (40X) in a section from 
randomly chosen tumors from vehicle-treated and cetuximab-treated mice bearing a PDX from the 
same original patient (n = 30). The plots show means ± SD. Statistical analysis by ratio paired t-test. 
Scale bar, 50 m. 
 
Figure 7. Targeting HER2/HER3 together with EGFR provides long-term therapeutic benefits in 
PDX trials 
(A) Tumor volume changes in PDXs treated with the indicated modalities for 4 weeks. Cetuximab, 20 
mg/Kg (intraperitoneal injection twice a week); Pan-HER, 60 mg/Kg (intraperitoneal injection twice a 
week). Dots represent volume changes of individual mice, and plots show the means ± SD for each 
treatment arm. n = 5 to 12 animals per each treatment arm. Statistical analysis by two-tailed unpaired 
Welch’s t-test. Tumor variation outliers were excluded using the ROUT method (GraphPad Prism). 
Cetux, cetuximab. (B) Kaplan-Meier survival curves in PDXs after discontinuation of the indicated 
treatments. n = 5 to 10 animals per each treatment arm. Statistical analysis by Log-rank (Mantel-Cox) 
test. (C) Tumor volume changes in PDXs treated with the indicated modalities for 4 weeks. n = 5 
animals per each treatment arm. Statistical analysis as in A. (D) Kaplan-Meier survival curves in PDXs 
after discontinuation of the indicated treatments. n = 5 animals per each treatment arm. Statistical 
analysis as in B. (E) Morphometric quantitation of the phosphorylation of the indicated proteins in PDXs 
CRC0322 and CRC0542 after treatment with vehicle (until tumors reached an average volume of 1500 
mm3), cetuximab (5 weeks), or Pan-HER (5 weeks). At the end of treatment, 3 tumors from 3 different 
mice were explanted and subjected to immunohistochemical analysis. Each dot represents the value 
measured in one optical field (40x), with 2 to 10 optical fields per tumor depending on the extent of 
section area (n = 16 to 30). The plots show means ± SD. Statistical analysis by one-way ANOVA 
followed by Benjamini, Krieger and Yekutieli FDR correction. P-S6, phospho-S6; P-ERK, phospho-
ERK; P-HER2, phospho-HER2; P-HER3, phospho-HER3. Representative images for phospho-S6 and 
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SUPPLEMENTARY MATERIALS AND METHODS 
 
ChIP-seq analysis of PDXs 
Frozen PDX samples were disaggregated in ice-cold PBS in the presence of protease inhibitors. 
Tumor suspensions were cross-linked first with 2 mM disuccinimidyl glutarate (Covachem) and 
then with 1% formaldehyde (Fisher). Chromatin was sonicated in IP Buffer (100 mmol/L Tris pH 
8.6, 0.3% SDS, 1.7% Triton X-100, and 5 mmol/L EDTA) to an average length of 500-1000 bp. 
Samples were immunoprecipitated overnight at 4°C with a rabbit anti--catenin antibody (Cell 
Signaling Technology). Purified DNA was sonicated to an average length of 200 bp and used for 
library preparation. Sequencing data were analyzed using QARI and PMS modules of the EpiMINE 
software (56). 
 
Immunohistochemistry and morphometric analyses 
Tumors were formalin-fixed, paraffin-embedded, and subjected to hematoxylin-and-eosin or 
immunoperoxidase staining with the following antibodies: mouse anti-Ki-67 (Dako); rabbit anti-
phospho-S6 (Ser235/236), rabbit anti-phospho-ERK (Thr202/Tyr204), rabbit anti-cleaved 
caspase-3, rabbit anti-pospho-HER2 (Tyr1248), rabbit anti phospho-HER3 (Tyr1289), all from Cell 
Signaling Technology; mouse anti-5 defensin (Abcam); mouse anti-YAP (Santa Cruz 
Biotechnology); mouse anti-β-catenin (BD Biosciences); rabbit anti--catenin (Cell Signaling). After 
incubation with secondary antibodies, immunoreactivities were revealed by incubation in DAB 
chromogen (Dako). Images were captured with the Leica LAS EZ software using a Leica DM LB 
microscope. Morphometric quantitation was performed by ImageJ software using spectral image 
segmentation. For double-staining experiments, the VECTOR® VIP Peroxidase Substrate Kit 
(Vector Laboratories) was employed. Antigens detected by Phospho-HER2, phospho-HER3, and 
rabbit β-Catenin antibodies were revealed by rabbit secondary antibody followed by DAB; 5 
defensin immunoreactivity was revealed by mouse secondary antibody and VECTOR® VIP purple 
chromogen. Morphometric quantitation was performed by image J software using color 
deconvolution segmentation. Software outputs were manually verified by visual inspection of digital 
images. 
 
Gene expression analyses 
For RT-qPCR experiments, total RNA was extracted using the Maxwell® Instrument (Promega) 
and reverse-transcribed using High-Capacity cDNA reverse transcription (Life Technologies). 
Results were normalized to the average of two housekeeper genes. The Taqman probes (all 
provided by ThermoFisher except for ASCL2, which was purchased from Integrated DNA 
Technologies) are listed in data file S6. For RNA-seq analysis, 1.5 to 2.5 μg RNA were sequenced 
using the TruSeq stranded mRNA kit from Illumina. FastQ files were processed with the Salmon 
tool, quality-checked with multiQC and normalized for quality assessment. Principal component 
analysis was then performed on the gene expression profiles. For microarray experiments, RNA 
was extracted using the miRNeasy Mini Kit (Qiagen). Synthesis of cDNA and biotinylated cRNA 
was performed using the IlluminaTotalPrep RNA Amplification Kit (Ambion). Quality assessment 
and quantitation of total RNA and cRNAs were performed with Agilent RNA kits on a Bioanalyzer 
2100 (Agilent). Hybridization of cRNAs was carried out using Illumina Human 48k gene chips 
(Human HT-12 V4 BeadChip). Array washing was performed by Illumina High Temp Wash Buffer 
for 10’ at 55°C, followed by staining using streptavidin-Cy3 dyes (Amersham Biosciences). 
Hybridized arrays were stained and scanned in a Beadstation 500 (Illumina). For bioinformatic 
analyses of microarray data, probe intensity data were extracted using the Illumina Genome Studio 
software (Genome Studio V2011.1) and subjected to Loess normalization using the Lumi R 
package. To minimize the noise, probes that generated detectable signals due to cross-species 
hybridization of transcripts deriving from murine infiltrates in PDX tissues were removed from the 
analysis. Finally, for each gene the probe displaying the highest signal variance among those that 
were detected (Genome Studio detection P = 0) was selected for further analyses. GSEA was 
performed using the dedicated software (software.broadinstitute.org/gsea/index.jsp); the statistical 
significance of enrichment was estimated based on default settings and 1000 gene permutations. 
IPA was applied to signatures of genes modulated by cetuximab by at least 2 folds. Enrichment 
(chi-square P) was estimated against the “large intestine” and “colon cancer cell lines” background 
provided by the IPA software. Gene expression microarray data generated in the course of this 
study have been deposited in the GEO database with accession number GSE108277. 
 
Genomic analyses  
For WES, exome libraries were generated from 200 ng DNA using the Agilent SureSelectXT2 
Human All Exon V5 Kit and were sequenced on the Illumina HiSeq2500 platform. Median coverage 
achieved after duplicates was 45x and 62x for CRC0252 and CRC0542, respectively. Adapter 
trimming was performed with Skewer v0.1.126 with minimum read length after trimming of 35 and 
mean quality value before trimming of 10. Trimmed reads were aligned to the full human reference 
genome hg19 with Burrows-Wheeler Aligner (BWA) v0.7.12. PCR duplicates were marked using 
Picard tools. Joint mutation calling between multiple samples from the same patient was performed 
using Platypus v0.8.1. Previously sequenced normal sample was used as reference for somatic 
variant calling (20). The following filtering criteria were used to call somatic variants in WES 
samples: i) only variants with Platypus filter PASS, alleleBias, Q20, QD, SC and HapScore were 
kept; ii) minimum coverage and genotype quality of 10 was required; iii) variants in segmental 
duplicated regions and centromeric regions were removed; iv) a minimum of 3 reads covering the 
variant in at least one of the tumor samples per patient were considered; v) 0 number of reads 
covering the variant in the germline sample; and vi) genotype 0/0 in the germline sample. Only 
somatic alterations and indels with a variant allele frequency higher than 5% were considered. 
 
Cell cultures, reagents, vectors, viral infection, and YAP reporter assays 
NCI-HCA46 cells were purchased from Sigma Aldrich and were cultured in DMEM; DiFi cells (from 
J. Baselga) were cultured in F12. The genetic identity of cell lines was validated by short tandem 
repeat profiling (Cell ID, Promega). CRC0078 colospheres were maintained as described (57) in 
the presence of 20 ng/ml EGF. BTC and doxycycline were from Sigma Aldrich. Targeted agents 
for in vivo or in vitro studies included: cetuximab (Merck); trastuzumab (Roche); Pan-HER and the 
isolated HER2 and HER3 components of Pan-HER (Symphogen); selumetinib, dactolisib, alpelisib 
(Carbosynth); BMS345541, ruxolitinib, PLX4720, everolimus, pictilisib, MK2206, and buparlisib 
(Selleck Chemicals). YAP-5SA (mutation sites: S61A, S109A, S127A, S164A, S381A) was cloned 
into the PS100069 lentiviral vector (Origene) for constitutive expression and into the Lenti-X™ Tet-
One™ Inducible Expression System-Puro (Takara) for doxycycline-regulated expression. The 
lentiviral vector expressing Myc-DDK-tagged wild type YAP was provided by Origene. The 
MISSION YAP-targeting shRNAs, as well as the non-targeting control vector, were from Sigma 





The TOP-GFP lentiviral vector was a gift from Laurie Ailles (Princess Margaret Cancer Center, 
University Health Network, Toronto, Canada). Lentiviral vectors were produced by LipofectAMINE 
2000 (Invitrogen)-mediated transfection of 293T cells (ATCC): To evaluate YAP activity, cells at 80 
% confluence were transiently transfected with the 8xGTIIC-luc YAP-reporter construct (Addgene) 
using LipofectAMINE 2000. Luciferase activity was assayed 72 h after transfection using the 
Luciferase Assay System (Promega) and a GloMax 96 microplate luminometer (Promega). For 
determination of 8xGTIIC-luciferase plasmid concentration, equivalent volumes of DNA were used. 
DCts were obtained by a 40-Ct transformation, and relative expression levels were expressed as 
2^DDCt (median centered). 
 
Biological assays 
On day 0, cells were plated at clonal density (20 cells/μl) in complete medium (for CRC0078, EGF 
was reduced to 4 ng/ml). On day 1, cells were treated as indicated in the figure legends. On day 2, 
apoptotic activity was measured using the caspase-Glo 3/7 luminescent assay kit (Promega). 
Results were normalized against viable cells, which were plated in parallel, treated with the same 
modalities, and assessed by ATP content (Cell Titer-Glo, Promega). Viability assays in the 
presence of BTC, cetuximab, trastuzumab, Pan-HER, or the isolated HER2 and HER3 components 
of Pan-HER were conducted for 72 h. Cell numbers were quantitated by ATP content. EDU 
incorporation in vitro was assessed using the Click-iT™ Plus EdU Cell Proliferation Kit for Imaging, 
Alexa Fluor™ 488 dye (Life Technologies). Organoids were incubated for 3 hours with 10 μM EdU 
prior to fixation and permeabilization; then, cells were stained with DAPI. EDU incorporation in vivo 
was examined by intraperitoneal injection (75 μg). Mice were sacrificed after 24h, and then tumors 
were explanted, formalin-fixed, paraffin-embedded and processed as described in (58). 
 
  
Western blot analysis 
Proteins were extracted with cold EB buffer (50 mmol/L Hepes pH 7.4, 150 mmol/L NaCl, 1% Triton 
X-100, 10% glycerol, 5 mmol/L EDTA, 5 mmol/L EGTA) in the presence of phosphatase and 
protease inhibitors. Lysates were run on precasted SDS-polyacrylamide gels (Invitrogen) and 
transferred to nitrocellulose membranes using a Trans-Blot Turbo Blotting System (Biorad). 
Membrane-bound antibodies were detected by the enhanced chemiluminescence system 
(Promega). Primary antibodies were the following: rabbit anti-phosho-EGFR (Tyr1068) (Abcam); 
rabbit anti-EGFR, rabbit anti-phospho-HER2 (Tyr1248), rabbit anti-phospho-HER3 (Tyr1289), 
rabbit anti-phospho-AKT (Ser473), rabbit anti-AKT, rabbit anti-phospho-ERK (Thr202/Tyr204), 
rabbit anti-ERK, rabbit anti-phospho-YAP (Ser127), rabbit anti-phospho-YAP (Ser397), all from 
Cell Signaling Technology; mouse anti-vinculin and mouse anti--tubulin (Sigma-Aldrich); mouse 
anti-c-Myc Tag, rabbit anti-YAP, and mouse anti-HER2, both from Santa Cruz Biotechnology; 






Figure S1. Biological characterization of residual disease after prolonged treatment with 
cetuximab in representative mCRC PDXs 
(A) Morphometric quantitation of proliferation (left panels) and apoptosis (right panels) in PDX 
models CRC0078 and CRC0096 treated with cetuximab (20 mg/kg twice a week intraperitoneally) 
for 12 weeks. At the indicated times, tumors were explanted and subjected to immunohistochemical 
analysis. Bars are the means ± SD of 10 optical fields (Ki67, 40X) or 5 optical fields (caspase 3, 
20X) for each time point for each tumor (n = 20 to 30 for Ki67 and n = 5 to 15 for active caspase 
3). Casp, caspase. (B) Left panels, morphometric quantitation and representative images of EdU 
incorporation in two PDXs from the reference collection after treatment with vehicle (until tumors 
reached an average volume of 1500 mm3) or cetuximab (for 6 weeks). At the end of treatment, 3 
tumors from 3 different mice were explanted and subjected to immunohistochemical analysis. Each 
dot represents the value measured in one optical field, with 10 optical fields per tumor (n = 30 for 
each condition). Right panels, morphometric quantitation and representative images of EdU 
incorporation in 3 PDX-derived organoids after treatment with vehicle or cetuximab (20 g/ml) for 
2 weeks. Results are the means ± SD of 3 biological replicates. Each dot represents the value 
measured in one optical field, with 25 optical fields per replicate (n = 75). Statistical analysis by 
two-tailed unpaired Welch’s t-test. Scale bar, 100 m (left panels) or 50 m (right panels). Cetux, 
cetuximab. (C) Upper panel, tumor growth curve showing the response of PDX model CRC0059 
over the course of a 21-week treatment with cetuximab, followed by therapy discontinuation and 
subsequent drug re-challenging. Values indicate the mean tumor volumes ± SEM (n = 6). Lower 
panel, representative hematoxylin-and-eosin images of the same case immediately before 
treatment, at maximal response (6 weeks), and 11 weeks after drug washout. Before treatment the 
tumor had a well-differentiated phenotype, with cells describing irregular pluristratified 
tubular/acinar structures with multiple lumens embedded in a scarce stromal matrix. The post-
treatment tissue at maximal response displayed reduced cellularity and pseudoglandular remnants 
scattered among large necrotic areas. After regrowth, the tumor re-acquired the histopathological 




Figure S2. Analysis of adaptive changes versus clonal selection induced by cetuximab in 
representative mCRC PDXs 
(A) Schematic of the changes in clonal mutational load when drug resistance is heritable (e.g. 
genetically driven). Phylogenetic trees illustrate how selection for a subclonal mutation (subtree, 
upper right panel) in a heterogeneous population consisting of sensitive (blue dots) and resistant 
(red dots) cells results in a greater load of clonal/truncal mutations (purple circles) following drug-
induced selection and after therapy cessation, due to the drug-induced population bottleneck. (B) 
Schematic of the changes in clonal mutational load when drug resistance is driven by non-heritable 
or plastic phenotypes. Nodes in the phylogenetic trees are coloured according to a stochastically 
determined non-heritable phenotype. Surviving cells are an unbiased sub-sample of the 
population, leaving the number of clonal/truncal mutations unchanged. Drug exposure initially 
renders the population homogeneous; however, phenotypic heterogeneity returns when therapy 
ceases. (C) Number of clonal mutations (variant allele frequency greater than or equal to 0.3) 
detected by whole exome sequencing analysis of untreated tumors (Vehicle), cetuximab-treated 
samples (Cetux), and tumors that had relapsed following drug withdrawal (Release) in PDX models 
CRC0252 and CRC0542. Bars refer to the number of replicates. (D) Scatter plots showing the 
mean variant allele frequency of all detected somatic mutations in cetuximab-treated samples and 




Figure S3. ChIP-seq analysis of residual disease after prolonged treatment with cetuximab 
in representative mCRC PDXs 
Upper panels, genomic snapshots of CTNNB1 ChIP-seq signal at 3 -catenin target loci from the 
indicated tumors after treatment with vehicle (until tumors reached an average volume of 1500 
mm3) or cetuximab (for 6 weeks). Lower panels, cumulative CTNNB1 normalized ChIP-seq 
intensity from the indicated tumors and conditions at CTNNB1-enriched genomic loci +/-4kb to the 




Figure S4. Longitudinal analysis of -catenin expression at different time points during 
prolonged treatment with cetuximab in representative mCRC PDXs  
Representative images of -catenin expression and localization in two PDX models treated with 
cetuximab (20 mg/kg twice a week intraperitoneally) and monitored longitudinally for 12 weeks. At 
the indicated times, tumors were explanted and subjected to immunohistochemical analysis. Scale 




Figure S5. GSEA of residual PDXs with signatures of Paneth cells and deep secretory cells  
Left panel: GSEA plot showing positive modulation of a Paneth cell signature, obtained in in the 
mouse small intestinal epithelium (30), in PDXs treated with cetuximab (GSE108277). Right panel: 
GSEA plot showing no enrichment for a signature of Reg4+ deep crypt secretory cells, which serve 
as Paneth cell equivalents in the murine colon (31), in PDXs treated with cetuximab. NES, 






Figure S6. DEFA5 and -catenin double staining in representative mCRC PDXs treated with 
cetuximab 
DEFA5 and -catenin double staining in 2 PDX models treated with cetuximab (20 mg/kg twice a 
week intraperitoneally) for 6 weeks. For each model, the upper panels are representative images 
of bright-field optical sections. The lower panels show the corresponding color deconvolution 




Figure S7. Transcript and protein changes of Paneth-cell markers and global gene 
expression variations in representative mCRC PDXs during different time points of 
cetuximab treatment and after therapy suspension 
(A) Heatmap showing expression changes for the indicated secretory/Paneth cell markers in 2 
representative PDXs treated with cetuximab (20 mg/kg twice a week intraperitoneally) and 
monitored longitudinally for 12 weeks. At the indicated times, 1 tumor from 1 mouse was explanted 
and subjected to RT-qPCR analysis. Average expression of the 5-gene secretory/Paneth cell 
signature, Log2R relative to vehicle-treated tumors, for model CRC0078: 1 week, 1.72; 2 weeks, 
1.86; 6 weeks, 2.4; 12 weeks, 1.02. Average expression of the 5-gene secretory/Paneth cell 
signature, Log2R relative to vehicle-treated tumors, for model CRC0096: 1 week, 1.16; 2 weeks, 
0.92; 6 weeks, 2.68; 12 weeks, 2.94. (B) Morphometric quantitation of DEFA6 protein expression 
in the 2 PDX models treated with cetuximab and monitored longitudinally for 12 weeks. At the 
indicated times, tumors were explanted and subjected to immunohistochemical analysis. Bars are 
the means ± SD of 5 optical fields (20x) for each tumor (n = 5 to 15). (C) Heatmap showing 
expression changes for the indicated secretory/Paneth-cell markers in PDXs of the reference 
collection after acute treatment with cetuximab (tumor explant 72h after antibody administration), 
as assessed by RT-qPCR. Average gene expression, Log2R relative to vehicle-treated tumors: 
DEFA5 1.36, P < 0.0001; DLL1 1.57, P < 0.0001; ATOH1 1.45, P < 0.0001; DEFA6 1.31, P < 
0.0001; GFI1 1.01, P = 0.0001 by two-tailed Wilcoxon test. Benjamini-Hochberg FDR < 0.1 for all 
genes. (D) Heatmap showing expression changes for the indicated secretory/Paneth-cell markers 
in 5 representative PDX models after cetuximab withdrawal, when regrown tumors reached 
volumes of around 750 mm3. The antibody was discontinued after six weeks of treatment. Gene 
expression was assessed by RT-qPCR and normalized to cetuximab-treated tumors. Average 
gene expression of tumors after treatment discontinuation, Log2R relative to cetuximab-treated 
tumors: DEFA5 -8.75, P < 0.0111; DEFA6 -7.24, P = 0.007; DLL1 -3.01, P = 0.0283; GFI1 -2.31, 
P = 0.0037; ATOH1 -1.54, P = 0.2143 by two-tailed paired Student’s t-test. Benjamini-Hochberg 
FDR < 0.1 for all genes except ATOH1. (E) Scatter plot showing the two principal components of 
transcriptional variance (based on RNAseq analysis) in cetuximab-treated samples (Cetux, red 
dots), relapsed tumors after therapy discontinuation (Release, blue dots) and untreated tumors 




Figure S8. Expression of YAP and YAP targets in representative mCRC PDXs during 
different time points of cetuximab treatment and after therapy suspension  
(A) Representative images of YAP expression and localization in 2 PDX models treated with 
cetuximab (20 mg/kg twice a week intraperitoneally) and monitored longitudinally for 12 weeks. At 
the indicated times, tumors were explanted and subjected to immunohistochemical analysis. Scale 
bar, 50 m. (B) Heatmap showing expression changes (assessed by RT-qPCR analysis) for the 
indicated YAP targets after treatment with cetuximab (20 mg/kg twice a week intraperitoneally) in 
the 2 models shown in panel A. At the indicated times, 1 tumor from 1 mouse was explanted and 
subjected to RT-qPCR analysis. (C) Representative images of YAP expression and localization in 
3 PDX models after treatment with cetuximab for 24 hours and 6 weeks and after antibody 




Figure S9. Inhibition of YAP activity and expression of YAP-dependent genes by cetuximab 
in CRC cell lines 
(A) Western blot analysis (left) and densitometric quantitation (right) of YAP phosphorylation in DiFi 
and HCA46 cell lines treated for 1 hour with 20 g/ml cetuximab. Total YAP was used for 
normalization; vinculin was used as a loading control. Western blots for total YAP protein were run 
with the same lysates as those used for anti-phosphoprotein detection but on different gels. The 
images shown are representative of 2 (DiFi) or 3 (HCA46) experiments on independent biological 
replicates. The plots of densitometric analysis show means ± range (DiFi) or SD (HCA46), with 
values normalized against vinculin. P-YAP, phospho-YAP; ser127, serine 127; ser397, serine 397; 
Cetux, cetuximab. (B) RT-qPCR analysis of the indicated YAP target genes in DiFi and HCA46 
cells treated for 72h with cetuximab (20 μg/ml), selumetinib (1 μM), or dactolisib (250 nM). Three 
independent experiments were performed in technical triplicates. The plots show means ± SD. 






Figure S10. Expression of secretory/Paneth cell genes after YAP silencing in CRC cell lines 
(A) Transcript (left panel) and protein (right panels) expression of YAP in DiFi and HCA46 cells 
transduced with two different shRNA lentiviral vectors targeting YAP. For RT-qPCR, 3 independent 
experiments were performed in biological triplicates (n = 3). In western blots, vinculin was used as 
a loading control. Western blot images are representative of 2 experiments on independent 
biological replicates. (B) RT-qPCR analysis of Wnt target gene transcripts in DiFi and HCA46 cells 
after shRNA-based YAP silencing, compared with mock cells. Three independent experiments 
were performed in technical triplicates. The plots show means ± SD. Statistical analysis by one-





Figure S11. YAP-dependent regulation of Wnt target genes in CRC cell lines 
(A) Western blot analysis of total protein extracts from DiFi and HCA46 cells transduced with the 
control pLVX-IRES-Puro vector (mock), a lentiviral vector enabling constitutive expression of the 
Myc-DDK-tagged mutant YAP variant YAP-S5A (left panels), or a lentiviral vector encoding Myc-
DDK-tagged wild-type YAP (YAP-WT) (right panels). YAP-S5A and YAP-WT were detected using 
a Myc antibody. Vinculin was probed as a loading control. (B) Luciferase-based measurement of 
YAP reporter activity in DiFi and HCA46 cells stably transduced with constitutive YAP-5SA or wild-
type YAP and transiently transfected for 72h with the 8xGTIIC-luc YAP-reporter construct. 
Luciferase activity was normalized against reporter plasmid concentration as determined by DNA 
qPCR and expressed as arbitrary units (A.U.). Three independent experiments were performed in 
biological quadruplicates (n = 12). The plots show means ± SD. Statistical analysis by one-way 
ANOVA followed by Benjamini, Krieger and Yekutieli FDR correction. (C) RT-qPCR analysis of the 
indicated Wnt target genes in DiFi and HCA46 cell lines transduced with YAP-5SA or YAP-WT. 
Three independent experiments were performed in technical triplicates. The plots show means ± 











Figure S12. Modulation of YAP transcriptional activity by cetuximab and other inhibitors of 
the EGFR pathway in CRC cell lines  
Measurement of YAP transcriptional activity in DiFi and HCA46 cell lines after treatment for 48h 
with vehicle (DMSO), cetuximab (20 μg/ml), trametinib (100 nM), buparlisib (0.5 M), or alpelisib 
(1 M). Luciferase activity was normalized against reporter plasmid concentration as determined 
by DNA qPCR and expressed as arbitrary units (A.U.). Two independent experiments were 
performed in biological quadruplicates (n = 8). The plots show means ± SD. Statistical analysis by 




Figure S13. Expression/activity of doxycycline-inducible YAP-5SA and modulation of 
secretory/Paneth cell genes by EGFR pathway inhibition in vitro and in vivo 
(A) Luciferase-based measurement of YAP reporter activity in DiFi cells stably transduced with a 
doxycycline-inducible YAP-5SA Lenti-X™ Tet-One™ Expression System-Puro, transiently 
transfected for 72h with the 8xGTIIC-luc YAP-reporter construct, and either left untreated (control) 
or treated with doxycycline for 48 h. Luciferase activity was normalized against reporter plasmid 
concentration as determined by DNA qPCR and expressed as arbitrary units (A.U.). Two 
independent experiments were performed in biological triplicates (n = 6). The plots show means ± 
SD. Statistical analysis by two-tailed unpaired Welch’s t-test. Doxy, doxycycline. (B) 
Representative images of YAP expression in DiFi xenografts after treatment with doxycycline (50 
mg/kg daily oral gavage) for 1 week, compared with vehicle-treated (control) counterparts. Scale 
bar, 100 m (200 m for insets). (C) RT-qPCR analysis of the indicated Paneth-cell transcripts in 
CRC cell lines (DiFi and HCA46) and colospheres (CRC0078) treated with 20 g/ml cetuximab for 
72h. Three (DiFi, HCA46) or 4 (CRC0078) independent experiments were performed in technical 
triplicates. The plots show means ± SD. Statistical analysis by matched one-way ANOVA followed 
by Benjamini, Krieger and Yekutieli FDR correction. (D) RT-qPCR analysis of Paneth-cell 
transcripts in cell lines and organoids treated with the indicated inhibitors for 72h (cetuximab, 20 
g/ml; selumetinib, 1 μM; trametinib, 100 nM; dactolisib, 250 nM; buparlisib, 0.5 M; alpelisib, 1 
M). Three independent experiments were performed in technical triplicates. The effects of EGFR 
and MEK blockade were positively correlated (DiFi, cetuximab versus trametinib, r = 0.997; HCA46, 
cetuximab versus trametinib, r = 0.995; CRC0322, cetuximab versus selumetinib, r = 0.997; 
CRC0542, cetuximab versus selumetinib, r = 0.997, Pearson’s correlation coefficient). In contrast, 
transcriptional changes induced by PI3K pathway inhibition negatively correlated with those 
triggered by cetuximab (DiFi, cetuximab versus buparlisib, r = -0.832; cetuximab versus alpelisib, 
r = -0.855; HCA46, cetuximab versus buparlisib, r = -0.935; cetuximab versus alpelisib, r = -0.96; 
CRC0322, cetuximab versus dactolisib, r = -0.415; CRC0542, cetuximab versus dactolisib, r = -
0.356). Cetux, cetuximab. (E) RT-qPCR analysis of Paneth-cell transcripts in a PDX model treated 
for 3 weeks with the indicated inhibitors. Four samples for each condition were analyzed in 




Figure S14. Expression of secretory/Paneth cell genes after YAP silencing or YAP 
overexpression in vitro and in vivo 
(A) RT-qPCR analysis of the indicated secretory/Paneth-cell genes in DiFi and HCA46 cells after 
shRNA-based YAP silencing, compared with mock cells. Three independent experiments were 
performed in technical triplicates. (B) RT-qPCR analysis of the indicated secretory/Paneth-cell 
genes in DiFi and HCA46 cell lines transduced with YAP-5SA or YAP-WT. Four (DiFi) or 3 (HCA46) 
independent experiments were performed in technical triplicates. To quantitate gene expression 
downregulation, technical triplicates consisting of one or two undetermined cycle threshold (Ct) 
values together with one or two detectable Ct > 37 were equalized to a Ct value of 40. (C) RT-
qPCR analysis of the indicated secretory/Paneth-cell genes in established DiFi xenografts 
transduced with doxycycline-inducible YAP-5SA and treated with doxycycline (50 mg/kg daily). 
Four samples for each condition were analyzed in technical triplicates. In all panels, the plots show 
means ± SD. For all experiments, statistical analysis was performed by one-way ANOVA followed 









Figure S15. Modulation of EGFR family ligands in PDXs treated with cetuximab 
Heatmap showing expression changes for the indicated EGFR ligands in PDXs of the reference 
collection, after treatment with cetuximab, as assessed by RT-qPCR. Average gene expression, 
Log2R relative to vehicle-treated tumors: AREG -0.28, P = 0.206; EREG -0.71, P = 0.004; EGF -
0.67, P = 0.349; HBEGF -0.56, P = 0.220; TGF (TGFA) -0.1, P = 0.766; BTC 0.6, P = 0.001 by 





Figure S16. Effects of individual signal inhibition and dual blockade of EGFR and PI3K or 
EGFR and MEK in CRC cell cultures  
(A) Luciferase-based evaluation of apoptosis (assessed by caspase 3/7 activity) in DiFi and HCA46 
cell lines either left untreated (vehicle, DMSO, grey bars) or exposed for 24h to the indicated drugs, 
used as monotherapy at the following concentrations: cetuximab, 20 g/ml; BMS345541 (IkB/IKK 
inhibitor), ruxolitinib (JAK1/JAK2 inhibitor), selumetinib (MEK1 inhibitor), PLX4720 (BRAF 
inhibitor), alpelisib (PI3Kα inhibitor), 1 M; dactolisib (PI3K/mTOR inhibitor), 250 nM; everolimus 
(mTOR inhibitor), 50 nM; pictilisib (PI3Kα/δ inhibitor), 100 nM; MK2206 (AKT inhibitor), 0.5 M; 
buparlisib (Pan-PI3K inhibitor), 0.5 M. Results represent the means ± SD of 2 independent 
experiments performed in biological quintuplicates (n = 10). Values shown for cetuximab 
monotherapy and Y axis scale are the same as in main Figure 5 for comparative purposes. (B) 
Western blot analysis of AKT and ERK phosphorylation in DiFi and HCA46 cell lines treated for 2 
h with dactolisib (250 nM), alpelisib (1 M) and/or for 24 h with cetuximab (20 g/ml). Total ERK 
and AKT were used for normalization; vinculin was used as a loading control. Western blots for 
total proteins were run with the same lysates as those used for anti-phosphoprotein detection but 
on different gels. The images shown are representative of 2 experiments on independent biological 
replicates. Cetux, cetuximab. P-AKT, phospho-AKT; P-ERK, phospho-ERK. (C) Analysis of 
combination index (CI) to assess drug interaction effects in CRC0078 colospheres embedded in 
PuraMatrix and treated for 2 weeks with the indicated drugs and concentrations. A dose-response 
matrix design was applied, and CI values were calculated by the Compusyn software using the 
equatorial areas of colospheres as proxies of cell viability. CI > 1 designates antagonism, CI = 1 
indicates an additive effect, and CI < 1 is defined as synergy. Cetuximab and dactolisib exhibited 
a synergistic effect at all concentrations tested (CI ranging from 0.007 to 0.822). The synergy 
between cetuximab and selumetinib occurred only at low compound concentrations and was less 




Figure S17. Effects of cetuximab on downstream signals in vitro and in vivo 
(A) Western blot analysis of AKT and ERK phosphorylation in DiFi and HCA46 cell lines and in 
CRC0078 colospheres treated for 24h (cell lines) or 72h (CRC0078) with cetuximab at the indicated 
concentrations. Total ERK and AKT were used for normalization; tubulin was used as a loading 
control. Western blots for total proteins were run with the same lysates as those used for anti-
phosphoprotein detection but on different gels. The images shown are representative of 2 (DiFi, 
HCA46) or 3 (CRC0078) experiments on independent biological replicates. Cetux, cetuximab; P-
ERK, phospho-ERK; P-AKT, phospho-AKT. (B) Morphometric quantitation (upper panels) and 
representative images (lower panels) of phospho-ERK and phospho-S6 immunoreactivity in PDXs 
from the reference collection after treatment with vehicle (until tumors reached an average volume 
of 1500 mm3) or cetuximab (20 mg/kg twice a week for 6 weeks). Each dot represents the average 
of 10 optical fields (40X) in a section from randomly chosen tumors from vehicle-treated and 
cetuximab-treated mice bearing a PDX from the same original patient (n = 30). The plots show 
means ± SD. Statistical analysis by two-tailed paired Student’s t-test. Scale bar, 50 m. P-S6, 
phospho-S6. (C) Morphometric quantitation of phospho-S6 and phospho-ERK immunoreactivity in 
5 representative PDX models after treatment with vehicle (until tumors reached an average volume 
of 1500 mm3) or cetuximab (20 mg/kg twice a week for 6 weeks). Results are also shown for 
matched cases after antibody withdrawal, when regrown tumors reached volumes of around 750 
mm3. At endpoints, 3 tumors from 3 different mice were explanted and subjected to 
immunohistochemical analysis. Each dot represents the value measured in one optical field (40x), 
with 2 to 10 optical fields per tumor depending on the extent of section area (n = 20 to 30). The 
plots show means ± SD. Statistical analysis by one-way ANOVA followed by Benjamini, Krieger 




Figure S18. Effects of PI3K inhibitors on downstream signals and tumor growth in vivo 
(A) Morphometric quantitation of phospho-S6 and phospho-ERK immunoreactivity in PDXs treated 
with vehicle (until tumors reached an average volume of 1500 mm3), dactolisib alone (35 mg/Kg, 
daily oral gavage) or alpelisib alone (25 mg/Kg, daily oral gavage) for 4 weeks (CRC0069) or 3 
weeks (CRC0252). In the case of CRC0252, the experiment was terminated at 3 weeks because 
some mice had to be euthanized upon reaching of the humane endpoint. (B) Morphometric 
quantitation of phospho-S6 and phospho-ERK immunoreactivity in PDXs treated with vehicle (until 
tumors reached an average volume of 1500 mm3), cetuximab alone (4 weeks), cetuximab and 
dactolisib (4 weeks) or cetuximab and alpelisib (4 weeks). Cetuximab, 20 mg/Kg (intraperitoneal 
injection twice a week); dactolisib, 35 mg/Kg (daily oral gavage); alpelisib, 25 mg/Kg (daily oral 
gavage). In both (A) and (B), at the end of treatment 3 tumors from 3 different mice (2 tumors from 
2 different mice in CRC0096 treated with alpelisib and cetuximab) were explanted and subjected 
to immunohistochemical analysis. Each dot represents the value measured in one optical field 
(40x), with 3 to 10 optical fields per tumor depending on the extent of section area (n = 10 to 30). 
The plots show means ± SD. Statistical analysis by two-tailed unpaired Welch’s t-test (A) or one-
way ANOVA followed by Benjamini, Krieger and Yekutieli FDR correction (B). (C) Tumor volume 
changes in the indicated cases treated with dactolisib alone or alpelisib alone for 4 weeks 
(CRC0069, CRC0096) or 3 weeks (CRC0252). Dots represent volume changes of individual mice, 




Figure S19. Effects of PI3K inhibition and combined EGFR and PI3K inhibition on mCRC 
PDX macroscopic residual disease (pre-treatment and end-of-treatment tumor volumes) 
Tumor volumes in PDXs treated with the indicated modalities for 4 weeks. Cetuximab, 20 mg/Kg 
(intraperitoneal injection twice a week); dactolisib, 35 mg/Kg (daily oral gavage); alpelisib, 25 
mg/Kg (daily oral gavage). Dots represent tumor volumes in individual mice, and plots show the 
means ± SD for each treatment arm. n = 4 to 14 animals per each treatment arm. Cetux, cetuximab; 





Figure S20. Effects of combined EGFR and PI3K inhibition on mCRC PDX microscopic 
residual disease, apoptosis, and survival 
(A) Microscopic assessment of residual cancer cell burden in PDXs treated with the indicated 
modalities for 4 weeks. Cetuximab, 20 mg/Kg (intraperitoneal injection twice a week); dactolisib, 
35 mg/Kg (daily oral gavage); alpelisib, 25 mg/Kg (daily oral gavage). Upper panels indicate 
morphometric quantitations (n = 4 to 89 depending on the extent of section area); lower panels 
include hematoxylin-and-eosin staining and visualization of cancer cells (in brown) by digital 
segmentation. Statistical analysis by two-tailed unpaired Welch’s t-test. Cetux, cetuximab. (B) 
Morphometric quantitation of apoptosis (caspase 3 staining) in PDXs treated for 24 hours with the 
indicated modalities. After treatment, 3 tumors from 3 different mice were explanted and subjected 
to immunohistochemical analysis. Each dot represents the value measured in one optical field 
(20x), with 3 to 10 optical fields per tumor depending on the extent of section area (n = 10 to 30). 
The plots show means ± SD. For CRC0069, CRC0252, CRC0322, CRC0542, and CRC0743, 
statistical analysis was performed by two-tailed unpaired Welch’s t-test. For CRC0096 and 
CRC0078, statistical analysis was performed by one-way ANOVA followed by Benjamini, Krieger 
and Yekutieli FDR correction. Casp, caspase. (C) Kaplan-Meier survival curves in PDXs after 
discontinuation of the indicated treatments. n = 6 to 9 animals per each treatment arm. Statistical 




Figure S21. YAP-dependent transcriptional modulation of HER2 and HER3 in CRC cell lines 
(A and B) RT-qPCR analysis of HER2 and HER3 transcript expression in DiFi and HCA46 cell 
lines transduced with constitutive active YAP (YAP-5SA) (A) or wild-type YAP (YAP-WT) (B). (C) 
RT-qPCR analysis of HER2 and HER3 transcript expression in DiFi and HCA46 cell lines 
transduced with a pLVX-control vector (mock) or wild-type YAP (YAP-WT), and treated with 
cetuximab (20 μg/ml) for 72h. (D) RT-qPCR analysis of HER2 and HER3 transcript expression in 
DiFi and HCA46 cells after shRNA-based YAP silencing, compared with mock cells. In all panels, 
the plots show means ± SD. In panel (A), 4 (DiFi) or 3 (HCA46) independent experiments were 
performed in technical triplicates. In all other panels, 3 independent experiments were performed 
in technical triplicates. Statistical analysis was performed by one-way ANOVA followed by 




Figure S22. Modulation of HER2 and HER3 expression in PDXs during prolonged treatment 
with cetuximab  
Heatmap showing expression changes for the indicated secretory/Paneth cell markers in 2 
representative PDXs treated with cetuximab (20 mg/kg twice a week intraperitoneally) and 
monitored longitudinally for 12 weeks. At the indicated times, 1 tumor from 1 mouse was explanted 





Figure S23. DEFA5 and HER2/HER3 double staining in representative mCRC PDXs treated 
with cetuximab 
HER2 or HER3 and -catenin double staining in 2 PDX models treated with cetuximab (20 mg/kg 
twice a week intraperitoneally) for 6 weeks. For each model, the upper panels are representative 
images of bright-field optical sections. The lower panels show the corresponding color 





Figure S24. CRC cell line sensitivity to individual targeting of HER family members  
Quantitation of cell number (assessed by ATP content) in DiFi and HCA46 cell lines treated for 72h 
with the indicated antibodies at the indicated concentrations in the absence or presence of 10 ng/ml 
BTC. Results represent the means ± SD of 2 independent experiments performed in biological 
triplicates (n = 6). HER2, anti-HER2 isolated component of Pan-HER; HER3, anti-HER3 isolated 




Figure S25. Effects of cetuximab and Pan-HER on EGFR downstream targets in vivo 
Representative images (right panels) of phospho-S6 and phospho-ERK immunoreactivity (see 
main Figure 7 for quantitations) in PDXs after treatment with vehicle (until tumors reached an 
average volume of 1500 mm3), cetuximab (20 mg/Kg, intraperitoneal injection twice a week for 5 
weeks), or Pan-HER (60 mg/Kg, intraperitoneal injection twice a week for 5 weeks). At the end of 
treatment, 3 tumors from 3 different mice were explanted and subjected to immunohistochemical 
analysis. Cetux, cetuximab; P-S6, phospho-S6; P-ERK, phospho-ERK. Scale bar, 50 m. 
